Incyte Corporation  Page 1 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3   10 NOV 2020  
CONFIDENTIAL  Clinical Study Protocol  
INCB  [ZIP_CODE] -308 
A Double -Blind, Vehicle -Controlled, Randomized Withdrawal and 
Treatment Extension Study to Assess the Long -Term Efficacy and 
Safety of Ruxolitinib Cream in Participants With Vitiligo 
(TRuE -V LTE)  
Product:  Ruxolitinib Cream  
IND Number:   
EudraCT Number:  2020 -000987 -53 
Phase of Study:  3 
Sponsor:  Incyte Corporation  
1801 Augustine Cut -Off 
Wilmington, DE [ZIP_CODE]  
Original Protocol:  19 MAR 2020  
Protocol Amendment 1:  28 SEP 2020  
Protocol Amendment 2:  [ADDRESS_1032390] their origin in the Declaration of 
Helsinki and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and applicable laws 
and country -specific regulations in which the study is being conducted.  
The information in this document is confidential.  No part of this information may be duplicated, referenced, or 
transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written consent.  

Incyte Corporation  Page 2 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  INVESTIGATOR'S AGREE MENT  
I have read the INCB [ZIP_CODE] -308 Protocol (Amendment 2 dated 10 NOV  2020) and agree to 
conduct the study as outlined .  I agree to maintain the confidentiality of all information received 
or developed in connection with this Protocol.  
 
 
   
(Printed Name [CONTACT_7919])    
   
   
(Signature [CONTACT_7919])   (Date)  
Incyte Corporation  Page [ADDRESS_1032391] OF ABBREVIATION S ................................ ................................ ................................ .......... 7 
1. PROTOCOL SUMMARY  ................................ ................................ ............................ 9 
2. INTRODUCTION  ................................ ................................ ................................ ......15 
2.1. Background  ................................ ................................ ................................ ................. 15 
2.1.1.  Preclinical Safety  ................................ ................................ ................................ ........ 16 
2.1.2.  Clinical Pharmacokinetics  ................................ ................................ .......................... 16 
2.1.3.  Clinical Efficacy and Safety of Ruxolitinib Cream in Vitiligo  ................................ ..17 
2.2. Study Rationale  ................................ ................................ ................................ ........... 18 
2.2.1.  Scientific Rationale for Study Design  ................................ ................................ ........ 18 
2.2.2.  Justification for Dose  ................................ ................................ ................................ ..20 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 20 
3. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 22 
4. STUDY DESIGN  ................................ ................................ ................................ .......24 
4.1. Overall Design  ................................ ................................ ................................ ............ 24 
4.2. Overall Study Duration  ................................ ................................ ............................... 25 
4.3. Study Termination  ................................ ................................ ................................ ......25 
5. STUDY POPULATION  ................................ ................................ ............................. 26 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 26 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......27 
5.3. Lifes tyle Considerations  ................................ ................................ ............................. 27 
5.4. Screen Failures  ................................ ................................ ................................ ............ 27 
5.5. Replacement of Participants  ................................ ................................ ....................... 27 
6. STUDY TREATMENT  ................................ ................................ .............................. 28 
6.1. Study Treatments Administered  ................................ ................................ ................. 28 
6.2. Preparation, Handling, and Accountability  ................................ ................................ 29 
6.3. Measures to Minimize Bias:  Randomization and Blinding  ................................ .......30 
6.4. Study Treatment Compliance  ................................ ................................ ..................... 30 
6.5. Dose Modifications  ................................ ................................ ................................ .....31 
6.5.1.  Criteria and Procedures for Application Interruptions and Modifications of 
Study Drug  ................................ ................................ ................................ .................. 31 
6.5.2.  Criteria for Permanent Discontinuation of Study Drug  ................................ .............. 32 
6.6. Concomitant Medications and Procedures  ................................ ................................ .32 
Incyte Corporation  Page 4 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  6.6.1.  Permitted Medications and Procedures  ................................ ................................ ......32 
6.6.2.  Restricted Medications and Procedures  ................................ ................................ ......33 
6.6.3.  Prohibited Medications and Procedures  ................................ ................................ .....33 
6.7. Rescue Treatment  ................................ ................................ ................................ .......34 
6.8. Treatment After the End of the Study  ................................ ................................ ......... 34 
7. DISCONTINUATION OF S TUDY TREATMENT AND P ARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ..[ADDRESS_1032392] to Follow -Up................................ ................................ ................................ .......35 
8. STUDY ASSESSMENTS AND PROC EDURES  ................................ ...................... 36 
8.1. Administrative and General Procedures  ................................ ................................ .....36 
8.1.1.  Informed Consent Process  ................................ ................................ .......................... 36 
8.1.2.  Eligibility Procedures  ................................ ................................ ................................ .37 
8.1.3. Interactive Response Technology Procedure  ................................ .............................. 37 
8.1.4.  Distribution of Reminder Cards and Diaries  ................................ .............................. 37 
8.2. Efficacy Assessments  ................................ ................................ ................................ .38 
8.2.1.  Body Surface Area  ................................ ................................ ................................ ......38 
8.2.2.  Vitiligo Area Scoring Index  ................................ ................................ ........................ 38 
 39 
 39 
8.2.5.  Photography  ................................ ................................ ................................ ................ 39 
8.2.6.  Patient -Reported Outcomes  ................................ ................................ ........................ 40 
[IP_ADDRESS].  Vitiligo Noticeability Scale  ................................ ................................ ........................ 40 
41 
41 
41 
[IP_ADDRESS].  Dermatology Life Quality Index  ................................ ................................ ................ 41 
42 
42 
8.3. Safety Assessments  ................................ ................................ ................................ .....42 

Incyte Corporation  Page 5 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  8.3.1.  Adverse Events  ................................ ................................ ................................ ........... 43 
8.3.2.  Physi cal Examinations  ................................ ................................ ................................ 43 
8.3.3.  Vital Signs  ................................ ................................ ................................ .................. 43 
8.3.4.  Laboratory Assessments  ................................ ................................ ............................. 44 
[IP_ADDRESS]. Pregnancy Testing  ................................ ................................ ................................ ......44 
8.4. Pharmacokinetic Assessments  ................................ ................................ .................... 45 
8.5. Pharmacodynamic and Translational Assessments  ................................ .................... 45 
8.6. Unscheduled Visits  ................................ ................................ ................................ .....45 
8.7. End of Treatment and/or Early Termination  ................................ .............................. 45 
8.8. Safety Follow -Up ................................ ................................ ................................ ........ 46 
9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDU RES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND REPORTING  ...................... 46 
9.1. Definition of Adverse Event  ................................ ................................ ....................... 46 
9.2. Definition of Serious Adverse Event  ................................ ................................ .......... 47 
9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse Events  ......... [ADDRESS_1032393] Complaints  ................................ ................................ ................................ ....52 
9.9. Treat ment of Overdose  ................................ ................................ ............................... 53 
10. STATISTICS  ................................ ................................ ................................ .............. 53 
10.1.  Sample Size Determination  ................................ ................................ ........................ 53 
10.2.  Populations for Analysis  ................................ ................................ ............................. 53 
10.3. Level of Significance  ................................ ................................ ................................ ..54 
10.4.  Statistical Analyses  ................................ ................................ ................................ .....54 
10.4.1.  Efficacy Analysis  ................................ ................................ ................................ ........ 54 
10.4.2.  Safety Analyses  ................................ ................................ ................................ .......... 55 
[IP_ADDRESS].  Adverse Events  ................................ ................................ ................................ ........... 55 
[IP_ADDRESS].  Clinical Laboratory Tests  ................................ ................................ ........................... 55 
[IP_ADDRESS].  Vital Signs  ................................ ................................ ................................ .................. [ADDRESS_1032394] OF TABLES  
Table  1: Primary and Secondary Objectives and Endpoints  ................................ ....................... 9 
Table  2: Key Study Design Elements  ................................ ................................ ....................... 10 
Table  3: Schedule of Activities  ................................ ................................ ................................ .12 
Table  4: Objectives and Endpoints  ................................ ................................ ........................... 22 
Table  5: Study Treatment Information  ................................ ................................ ..................... 28 
Table  6: Guidelines for Interruption and Restarting of Study Drug  ................................ ......... 31 
 ..................... ................. 39 
 39 
Table  9: Required Laboratory Analytes  ................................ ................................ .................... 44 
Table  10: Populations for Analysis  ................................ ................................ ............................. [ADDRESS_1032395] OF FIGURES  
Figure  1: Study Design Schema  ................................ ................................ ................................ .[ADDRESS_1032396]  aspartate aminotransferase  
BID twice daily  
BSA  body surface area  
CDC  Centers for Disease Control and Prevention  
CDLQI  Children’s Dermatology Life Quality Index  
CFR  Code of Federal Regulations  
CO [ADDRESS_1032397]  
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
EMA  European Medicines Agency  
EOS  end of study  
EOT  end of treatment  
FAS Full Analysis Set  
F-BSA  facial body surface area  
F-VASI  Face Vitiligo Area Scoring Index  
F-VASI50/75/90  ≥ 50%/ 75%/ 90% improvement from baseline in Face Vitiligo Area Scoring 
Index score  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
HIV human immunodeficiency virus  
IB Investigator’s Brochure  
IC50 50% inhibitory concentration  
ICF informed consent form  
ICH International Conference on Harmonisation  
ID identification  

Incyte Corporation  Page [ADDRESS_1032398] operating procedure  
SPF sun protection factor  
S[LOCATION_003]R  suspected unexpected adverse reaction  
T-BSA  total body surface area  
TEAE  treatment -emergent adverse event  
T-VASI  total body Vitiligo Area Scoring Index  
T-VASI50/75/90  ≥ 50%/ 75%/ 90% improvement in tota l body Vitiligo Area Scoring Index  
TYK  tyrosine kinase  
ULN  upper limit of normal  
US [LOCATION_002] (of America)  
UV ultraviolet  
VASI  Vitiligo Area Scoring Index  
VNS  Vitiligo Noticeability Scale  
WHO  World Health Organization  

Incyte Corporation  Page 9 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  1. PROTOCOL  SUMMARY  
Protocol Title:   A Double -Blind, Vehicle -Controlled, Randomized Withdrawal and Treatment 
Extension Study to Assess the Long -Term Efficacy and Safety of Ruxolitinib  Cream in 
Participants With Vitiligo (TRuE -V LTE)  
Protocol Number:   INCB [ZIP_CODE] -308 
Objectives and Endpoints:  
Table  1 presents the primary and secondary endpoints and objectives.  
Table  1: Primary and Secondary Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the duration of clinical response of 
ruxolitinib cream in participants with vitiligo.  For participants who are randomized in Cohort A:  
• Time to relapse (defined as < F -VASI75).  
Key Secondary  
To evaluate the duration of clinical response of 
ruxolitinib cream in participants with vitiligo.  For participants who are randomized in Cohort A:  
• Time to  maintain ≥ F -VASI90 response.  
Secondary  
To further evaluate the efficacy of ruxolitinib 
cream.  • Proportion of participants who achieve 
F-VASI50/75/90 during the extension treatment 
period.  
• Actual measurements, change, and percentage 
change from baseline in F-VASI.  
• Proportion of participants who achieve 
T-VASI50/75/90 during the extension treatment 
period.  
• Actual measurements, change, and percentage 
change from baseline in T -VASI.  
• Actual measurements, change, and percentage 
change from baseline in F -BSA.  
• Actual measurements, change, and percentage 
change from baseline in T -BSA.  
• Proportion of participants achieving a VNS of 
“4 – A lot less noticeable” or “5 – No longer 
noticeable” during the extension treatment 
period.  
To determine the participants' quality  of life.  • Change from Week 52 in DLQI (or CDLQI) 
during the extension treatment period.  
To evaluate the safety and tolerability of 
ruxolitinib cream.  • The frequency and severity of AEs; includes 
performing physical examinations and 
collecting vital signs a nd laboratory data for 
hematology and serum chemistry.  
To evaluate the ruxolitinib PK in plasma after 
treatment with ruxolitinib cream.  • Trough plasma concentrations of ruxolitinib at 
Week 80 and Week 104.  
Incyte Corporation  Page 10 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  Overall Design:  
Table  2 presents the key study design elements.  Further study details are presented after the 
table.  
Table  2: Key Study Design Elements  
Study Phase  Phase 3  
Clinical Indication  Vitiligo  
Population  Male and female participants from Study INCB  [ZIP_CODE] -306 or Study 
INCB  [ZIP_CODE] -307 (parent studies) conducted in adults and adolescents with 
vitiligo who adequately completed the visits and assessments required for the 
treatment periods, as defined in the parent study protocol, and tolerated 
ruxolitinib cream treatment without safety concern for continuation.  
Number of 
Participants  Approximately 500  
Study Design  Double -blind, vehicle -controlled, random ized withdrawal (Cohort A) and 
treatment extension (Cohort A and Cohort B)  
Estimated Duration 
of Study 
Participation  Extension treatment period:  52 weeks  
Safety follow -up:  4 weeks (30 days) after last application of study treatment 
or last study visit  
Total:  Up to approximately  56 weeks  
DSMB  No 
Treatment Groups and Duration:  
This is a Phase 3, double -blind, vehicle -controlled, randomized withdrawal and treatment 
extension study that will enroll eligible participants who have completed either 
Study  INCB [ZIP_CODE] -306 or Study INCB  [ZIP_CODE] -307 (parent studies)  in which the participants will 
have been using ruxolitinib cream 1.5% BID for the previous 28 to 52 weeks (depending on their 
initial randomization in the parent study; see Figure  1).  Participants who successfully complete 
either of the parent studies and tolerated ruxolitinib treatment without safety concern and with 
good compliance for continuation may be eligible to participate in this treatment extension study.  
The parent study population comprised adolescent and adult participants (age ≥ 12 years) with 
non-segmental vitiligo who had depi[INVESTIGATOR_352829] ≥ 0.5% BSA on the fac e, 
≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, and ≥ 3 T -VASI, with total body involved vitiligo 
area (facial and nonfacial) that was not to exceed 10% BSA.  
Eligible participants in this treatment extension study will be assigned to one of 2 cohorts, 
Cohort  A or Cohort  B, based on their F -VASI responses at the time of enrollment in this 
extension study (ie,  at Week 52).  Participants who achieve complete or almost complete facial 
repi[INVESTIGATOR_371] (ie,  achieve ≥ F-VASI90) at Week 52 in the parent study will be assigned to 
Cohort  A, stratified by [CONTACT_754342] 1 of the parent study, and 
randomized 1:1 to treatment with vehicle cream BID or ruxolitinib cream 1.5%  BID for an 
additional 52  weeks (ie,  until EOT at Week  104).  However, a ny participants in Cohort  A who 
experience relapse (defined as < F -VASI75) will receive ruxolitinib cream 1.5% BID as an 
open -label rescue treatment until they complete treatment (Week  104 or EOT).  Participants who 
did not achieve ≥ F-VASI90 at Week 52 of  the parent studies will be assigned to Cohort B and 
Incyte Corporation  Page 11 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  will continue ruxolitinib cream 1.5% BID for 52 weeks (ie,  until EOT at Week  104).  For 
Cohort  A, the participant, investigator, and sponsor will remain blinded to treatment assignment; 
the treatment for  Cohort  B will be open -label.  
See Section  4.[ADDRESS_1032399].  
Figure  1: Study Design Schema  
 
1. All participants in Cohort A  will use their randomly assigned treatment (either vehicle or ruxolitinib cream) on both the face 
and total body.  
2. Rescue treatment :  If, at any time, a participant in Cohort A loses a clinically meaningful response on the face (< F -VASI75), 
the participan t will receive open -label 1.5% BID ruxolitinib cream until Week 104 or EOT.  

Incyte Corporation  Page 12 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2   Version 3     10 NOV 2020  
CONFIDENTIAL  Table  3: Schedule of Activities  
Evaluation  Parent 
Study  Extension Treatment Period  Safety 
Follow -Up 
Notes  Week 52 
(Parent 
Study)  
± 7 d  Enrollment  
(Week 52)  
± 7 da Weeks 56, 
60, and 64  
± 7 d  Week 68b 
± 7 d  Week 80b 
± 7 d  Week 92b 
± 7 d  Week 104b 
(EOT)  
± 7 d  30 Days 
After EOT 
(EOS)  
+ [ADDRESS_1032400] IRT   X X X X X X X  
Concomitant medications  X  X X X X X X  
Apply study drug   X X X X X    
Dispense (D) and return (R) 
study drug and diary cards  R D R/D R/D R/D R/D R   
Safety assessments  
AE assessment  X X X X X X X X  
Comprehensive physical 
examination  X      X   
Targeted physical 
examination     X X X  X A targeted physical examination 
should be conducted as indicated by 
[CONTACT_312361], AEs, or other findings.  
Abnormalities that are considered 
clinically significant in the 
judgment of the investigator  are to 
be reported as AEs.  See 
Section  8.3.2 . 
Vital signs  X  X X X X X X  
Efficacy assessments  
F-BSA  X  X X X X X X  
T-BSA  X  X X X X X X Includes facial and nonfacial areas.  
F-VASI  X  X X X X X X  
T-VASI  X  X X X X X X Includes facial and nonfacial areas.  

Incyte Corporation  Page 13 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2   Version 3     10 NOV 2020  
CONFIDENTIAL  Table  3: Schedule of Activities (Continued)  
Evaluation  Parent 
Study  Extension Treatment Period  Safety 
Follow -Up 
Notes  Week 52 
(Parent 
Study)  
± 7 d  Enrollment  
(Week 52)  
± 7 da Weeks 56, 
60, and 64  
± 7 d  Week 68b 
± 7 d  Week 80b 
± 7 d  Week 92b 
± 7 d  Week 104b 
(EOT)  
± 7 d  30 Days 
After EOT 
(EOS)  
+ 7 d  
Efficacy assessments (continued)  
Photography of face  X   X X X X X 2D photograph at all sites; 3D 
photography at selected sites.  
Photography of nonfacial 
target area  X   X X X X X 2D photography at all sites.  The 
genitalia area should not be 
photographed.  
Patient -reported outcomes  To be evaluated prior to any other 
study procedures/assessments.  
VNS  X  X X X X X X The participant will be provided 
their baseline photo and a mirror to 
perform this assessment.  
DLQI  X  X X X X X X For participants who are age 
< 16 years at baseline (Day 1) of the 
parent study, the CDLQI will be 
completed instead.  

Incyte Corporation  Page 14 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2   Version 3     10 NOV 2020  
CONFIDENTIAL  Table  3: Schedule of Activities (Continued)  
Evaluation  Parent 
Study  Extension Treatment Period  Safety 
Follow -Up 
Notes  Week 52 
(Parent 
Study)  
± 7 d  Enrollment  
(Week 52)  
± 7 da Weeks 56, 
60, and 64  
± 7 d  Week 68b 
± 7 d  Week 80b 
± 7 d  Week 92b 
± 7 d  Week 104b 
(EOT)  
± 7 d  30 Days 
After EOT 
(EOS)  
+ 7 d  
Laboratory assessments  
Hematology and chemistry 
assessments  X  X X X X X X  
Pregnancy testing  X*  X X X X X X* *Female participants of 
childbearing  potential will have a 
serum pregnancy test at Week  [ADDRESS_1032401].  
PK  assessments  
PK plasma sampling 
(trough)      X*  X  Time of last study drug application 
to be recorded in eCRF.  Blood 
samples must not be drawn from the 
area that has been treated with study 
drug.  
*Samples will be drawn at predose.  
Note:  Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical and laboratory tes ts may be performed, as clinically indicated.  
a All scheduled assessments for the Week [ADDRESS_1032402] 0.5% to 2% of the 
population worldwide ( Krüger and Schallreuter 2012 ) and is characterized by [CONTACT_61911][INVESTIGATOR_490504] a selective loss of melanocytes.  The natural course of the disease is 
generally unpredictable, but it is often progressive.  Some degree of spontaneous repi[INVESTIGATOR_490505] 10% to 20% of patients; h owever, it is typi[INVESTIGATOR_352832] 
(Castanet and Ortonne 1997 ). 
Vitiligo is considered a serious disease owing to its substantial psychological burden on patients 
and its progressive course if l eft untreated.  Involvement of exposed skin (eg, face and hands) 
can have a major negative impact on self -esteem and quality of life ( Silverberg and 
Silverberg  2013 ).  Studies also suggest that the onset of  vitiligo beginning in childhood can be 
associated with significant psychological trauma that may have long lasting effects on 
self-esteem ( Linthorst Homan et al 2008 ).  A majority of vitiligo sufferers feel their appearance  
is moderately to severely intolerable, are distressed about their disease, experience 
stigmatization, and have feelings of anxiety and embarrassment when meeting strangers or 
beginning a new sexual relationship ( Porter et al 1990 , Salzer and Schallreuter 1995 , Krüger 
et al 2014 ).  Additionally, based on various meta -analyses, patients with vitiligo are 
approximately 5 times more likely to suffer from depression than healthy controls ( Lai 
et al 2017 , Wang et al 2018 , Osinubi et al 2018 ). 
Currently, there is no approved drug treatment for vitil igo.  The management of vitiligo is 
empi[INVESTIGATOR_352834] (American Academy of 
Dermatology , Gawkrodger et al 2008 , Taieb et al 2013 , Vitiligo Research Foundation ).  In 
general, first -line treatments consist of topi[INVESTIGATOR_304266], which may be 
most useful for treating disea se that is localized.  However, this use is off -label, there are 
inconclusive (or insufficient) data supporting their efficacy, many have restrictions on duration 
of chronic use, and AEs can limit their tolerability.  Second -line treatments consist of 
phototherapy (NB -UVB and PUVA) and systemic steroid treatment.  However, phototherapy 
regimens typi[INVESTIGATOR_1435] 2 to 3 treatments per week, and 12 to 24  months of continuous 
phototherapy may be necessary to acquire maximal repi[INVESTIGATOR_371] ( Taieb et al 2013 ); relapses 
are common.  Third -line treatments consist of surgical grafting techniques and depi[INVESTIGATOR_490507].  Surgery is best indicated for stable and localized forms of vitiligo, and only a small 
number of patients w ith vitiligo are considered suitable candidates.  All of these treatments can 
have adverse effects that limit their use.  
No available product or therapy is able to modify the course of vitiligo disease and produce a 
long-lasting effect.  Given the lack of approved therapi[INVESTIGATOR_754315] [ADDRESS_1032403] 
TYK2 and JAK3.  Ruxolitinib potently (IC 50 < 5 nM) inh ibits JAKs, yet it does not significantly 
inhibit (< 30% inhibition) a broad panel of 26 kinases when tested at 200 nM (approximately 
100 times the average IC 50 value for JAK enzyme inhibition).  Ruxolitinib -mediated inhibition of 
JAK signaling may be an e ffective strategy for vitiligo treatment.  
2.1.1.  Preclinical Safety  
In preclinical studies, ruxolitinib cream did not act as a contact [CONTACT_754343].  Topi[INVESTIGATOR_754316] 1.5% QD for [ADDRESS_1032404] been observed along with lymphoid depletion in bone marrow and lymphoid organs.  
Syste mic exposures in these studies exceeded those anticipated with topi[INVESTIGATOR_59407].  
Ruxolitinib was not teratogenic when administered to pregnant rats or rabbits; there were no 
adverse developmental effects at doses below those associated with maternal to xicity.  In vitro 
testing also showed that ruxolitinib was not mutagenic or clastogenic.  
In a toxicity study of orally -administered ruxolitinib in juvenile rats beginning on Days 7, 14, or 
21 postpartum, dose -related effects on body weight gain and decreme nts in various bone 
measures were observed in all cohorts.  Hematology and other microscopic findings were similar 
to those previously observed in general toxicology studies.  Other than the bone findings, there 
were no other novel toxicities in juvenile a nimals.  In animals administered ruxolitinib orally 
beginning on Day 21 postpartum (considered approximately equivalent to a 2 -year-old human), 
bone findings occurred at exposures higher than those anticipated with topi[INVESTIGATOR_59407].  The 
clinical releva nce of these findings to humans is not clear.  
Further information on preclinical toxicology and safety is summarized in  ruxolitinib cream  
IB Sections  4.[ADDRESS_1032405] demonstrated that exposures of ruxolitinib were generally 
strength -dependent with a moderate interparticipant variability.  The systemic PK following 
topi[INVESTIGATOR_754317] (Study INCB [ZIP_CODE] -202) and AD (Study 
INCB  [ZIP_CODE] -206) is characterized by [CONTACT_754344] -order release, modest peak -to-trough 
excursion (ratio ~2), estimated relative bioavailability of 3% to 5%, and an apparent terminal 
elimination half -life of approximately 3 days.  The plasma metabolite profile following t opi[INVESTIGATOR_754318].  
Incyte Corporation  Page 17 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  Preliminary PK data are available from topi[INVESTIGATOR_754319] (Study 
INCB  [ZIP_CODE] -211).  Plasma ruxolitinib concentrations reached steady -state at o r before Week  4 
and were similar at Week 24/Week 28 after treatment of ruxolitinib cream.  Plasma 
concentrations of ruxolitinib for predose and 2.0 -hour postdose were similar, indicating a slow 
rate of absorption.  Application of ruxolitinib cream 0.15% QD , 0.5% QD, 1.5% QD, and 
1.5%  BID resulted in mean (range) plasma concentrations of 5.75 nM (0 -28.8 nM), 
12.6 nM (0-82.1 nM), 59.1 nM (0 -245 nM), and 113 nM (0 -662 nM), respectively, after 
24 weeks of treatment.  Plasma concentrations increased as dose stre ngth and frequency of 
dosing were increased.  
The ruxolitinib terminal half -life following oral administration is approximately 3 hours with no 
appreciable accumulation of either parent or metabolites with BID oral dosing.  However, the 
long apparent half -life (~4 days) observed in topi[INVESTIGATOR_754320], which acts as a depot (Study INCB [ZIP_CODE] -202).  Therefore, the plasma concentration of 
ruxolitinib (following its topi[INVESTIGATOR_59407]) reaches steady -state in 2 to 4  weeks and remains 
relatively unchanged after steady -state is reached, and this was confirmed in Study 
INCB  [ZIP_CODE] -203 and Study INCB [ZIP_CODE] -211. 
Preliminary PK data are available for adolescents (aged ≥  12 to 17  years) with AD (Study 
INCB  [ZIP_CODE] -102).  Plasma c oncentrations of ruxolitinib were time -dependent with higher 
concentrations on Day  1 and decreasing concentrations on Day  15 and Day  29.  The observed 
decrease in ruxolitinib blood levels at Week 4 probably relates to a changing proportion of 
diseased to h ealthy skin treated at that timepoint and immediately before it.  Steady -state plasma 
concentrations (based on geometric mean) following 1.5%  BID in adolescent participants is 
similar to that in adults, suggesting similar skin flux in the [ADDRESS_1032406] 0.5% BSA on the face and at 
least 3% BSA on nonfacial areas.  In the first p art of the study, a total of 157 participants were 
equally randomized to receive ruxolitinib cream 1.5% BID, 1.5% QD, 0.5% QD, 0.15% QD, or 
vehicle BID for 24  weeks.  In the second part of the study, all participants initially randomized to 
vehicle  BID and  participants initially randomized to 0.15% QD who did not achieve ≥ 25% 
improvement from baseline in F -VASI were re -randomized to 1 of the 3 higher dosing groups 
for an additional 28 weeks.  All other participants maintained the same treatment until Week 52.  
After Week 52, participants could receive open -label 1.5% BID for an additional 52 weeks.  The 
primary endpoint was the proportion of participants who achieved a ≥ 50% improvement from 
baseline in F -VASI50 at Week 24.  
All ruxolitinib treatment arms de monstrated clinically meaningful efficacy and superiority over 
vehicle.  The proportion of participants who achieved an F -VASI50 at Week 24 was statistically 
significantly greater for ruxolitinib cream versus vehicle with response rates of 32.3%, 25.8%, 
50.0%, and 45.5% for ruxolitinib cream 0.15% QD, 0.5% QD, 1.5% QD, and 1.5% BID, 
respectively, and 3.1% for vehicle.  The proportion of participants who achieved an F -VASI75 at 
Week 24 was also statistically significantly greater for ruxolitinib cream versus  vehicle with 
Incyte Corporation  Page 18 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  response rates of 9.7%, 16.1%, 16.7%, and 30.3% for ruxolitinib cream 0.15% QD, 0.5% QD, 
1.5%  QD, and 1.5% BID, respectively, and 0% for vehicle.  For the participants who were 
initially randomized to ruxolitinib cream 0.5% QD, 1.5% QD, and 1 .5% BID and continued on 
these treatments until Week 52, continued improvement in F -VASI response was observed with 
the proportion of participants who achieved an F -VASI75 at Week 52, demonstrating response 
rates of 29.0%, 30.0%, and 51.5% for ruxolitinib cream, respectively.  
Improvements in T -VASI were observed for both Week 24 and Week 52.  The proportion of 
participants who achieved a T -VASI50 at Week 24 was also statistically significantly greater for 
ruxolitinib cream 0.15% QD, 0.5% QD, 1.5% QD, and 1. 5% BID compared with vehicle with 
response rates of 16.1%, 6.5%%, 23.3%, and 12.1%, respectively, compared with 0% in 
vehicle -treated participants.  Continued improvement in participants treated with 0.5% QD, 
1.5%  QD, and 1.5%  BID through Week 52 was obser ved with response rates in T -VASI50 
of 25.8%, 30.0%, and 36.4%, respectively.  
All ruxolitinib treatment arms were generally safe and well -tolerated with no significant TEAEs 
or application site events and no clinically relevant hematological changes.  The TEAE rate 
overall was low and similar between active treatment and vehicle.  There were 4 SAEs through 
52 weeks, none of which were treatment -related.  Discontinuations from treatment through 
52 weeks was low.  Safety and tolerability were similar between the Week 24 and Week 52 
period.  
Efficacy and safety data from the ongoing Phase  3 studies in vitiligo  (INCB  [ZIP_CODE] -306 or 
INCB  [ZIP_CODE] -307) are not yet available.  
Further information on clinical efficacy and safety in vitiligo patients as well as other indica tions 
(psoriasis and AD) is summarized in  ruxolitinib cream  IB Section  5.3. 
2.2. Study Rationale  
This study is designed to evaluate the duration of response following withdrawal of ruxolitinib 
cream (Cohort A vehicle grou p) and maintenance of response with continued use of ruxolitinib 
cream in individuals with vitiligo who have experienced repi[INVESTIGATOR_754321].  This study is also designed to characterize the long -term efficacy and safety profile  of 
ruxolitinib cream in individuals with vitiligo treated for up to a total of [ADDRESS_1032407] that JAK inhibition is an effective 
therapeutic strategy to treat pati ents with vitiligo (see Section  2.1.3 ).  The objective of this 
extension study and its parent studies is to confirm and extend the Phase 2 study efficacy and 
safety findings for  ruxolitinib cream  in a larger patient population.  
The current Phase  3 extension study is designed to evaluate the long -term efficacy, safety, and 
tolerability of ruxolitinib cream.  Combined with data from its Phase  3 parent studies , this study 
will provide efficacy and safety data in patients with vitiligo treated for up to 104 weeks with 
ruxolitinib cream 1.5% BID.  
This extension study will enroll interested and eligible participants from the study population of 
the parent studies.  The eligibility criteria used in the parent studies were generally designed to 
enroll a representative segment of the vitiligo patient p opulation.  The parent studies enrolled 
Incyte Corporation  Page 19 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  both male and female participants  (the prevalence of vitiligo is similar between men and women ) 
with non -segmental (generalized) vitiligo, which is the most common type of vitiligo, accounting 
for up to 90%  of cases (Taieb et al 2009 ).  While the Phase 2 study enrolled participants 18  years 
or older, in the parent Phase 3 studies, participants ≥ 12 years of age were enrolled; this is 
important because almost  50% of vitiligo patients  present before 20 years of age ( Rodrigues 
et al 2017 ).  The emerging  safety profile supports enrolling this population of adolescents as 
ruxolitinib cream has been well -tolerated in the Phase 2 vitiligo study and th e AD studies, 
including Study INCB  [ZIP_CODE] -102, which enrolled participants with AD aged 12  to 18  years.  
Additionally, enrollment in the parent studies targeted participants who were amenable to topi[INVESTIGATOR_754322] ≥  0.5% BSA on the face,  
≥ 0.5 F-VASI , ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI,  and total body vitiligo area 
≤ 10% BSA (facial and nonfacial).  This extension study will thus be composed of participants 
meeting these same criteria.  
This study includes a 52-week vehicle group; however, participants randomized to vehicle will 
have already received at least 28 weeks of treatment with ruxolitinib cream 1.5% BID in the 
parent study, and only participants who have already achieved complete or near -complete 
response (ie, achieve ≥ F -VASI90) at the time of randomization in this extension study treatment 
will be subject to randomization to vehicle.  Additionally, if participants randomized to vehicle 
experience relapse ( < F-VASI75 ), they will receive open -label r escue treatment of ruxolitinib 
cream 1.5% BID until they treatment.  Thus, under the design of this study, no participants will 
go untreated if they experience a clinically meaningful recurrence after withdrawal of active 
treatment.  Including this vehicle  group for participants with ≥ F -VASI90 allows for a robust 
examination of the duration of response following ruxolitinib cream withdrawal.  
Inclusion of participants who have achieved ≥ F -VASI90 and are randomized to ruxolitinib 
cream 1.5% BID allows for a n assessment of the maintenance of response with continued use of 
ruxolitinib cream.  Additionally, inclusion of participants who did not achieve ≥ F -VASI90 and 
are assigned to ruxolitinib cream 1.5% BID allows for an assessment of the maintenance of 
respo nse and an evaluation of the time course of response with continued use of ruxolitinib 
cream in individuals who may be exhibiting slower response times.  For both of these groups, the 
additional 52 weeks of treatment in this extension study is designed to further evaluate the 
long-term efficacy and safety of ruxolitinib cream 1.5% BID treatment.  
The primary and key secondary endpoints in this study evaluate the duration of clinical response 
and the maintenance of response as measured by F -VASI.  VASI is rec ognized as a validated 
quantitative scale developed by [CONTACT_754345] ( 2004 ).  Areas affected by [CONTACT_61911][INVESTIGATOR_754323], which is a quantitative clinical tool that is analogous to  
the PASI used in psoriasis and is based on a composite estimate of the overall area of vitiligo 
patches at baseline and the degree of macular repi[INVESTIGATOR_312316].  In 
this extension study, both F -VASI and T -VASI will be evaluated .  F-VASI was the primary 
endpoint in the Phase [ADDRESS_1032408] the repi[INVESTIGATOR_754324].  In 
addition, from the patient’s perspe ctive, facial disease involvement has the strongest relevance 
on appearance and correlation to the patient’s psychological burden.  Prior to the earlier parent 
Phase  [ADDRESS_1032409] change.  T hese analyses of treatment efficacy support 
the clinical relevance of the F -VASI and T -VASI endpoints for vitiligo.  
Considering findings from the INFO study (International Initiative for Outcomes [INFO] for 
Vitiligo; Eleftheriadou et al 2012 ), INCB [ADDRESS_1032410] to the 
Phase  2 study, the primary outcome measure is the F -VASI75 as this repr esents a higher degree 
of response for the face.  The VNS has been included as a secondary measure.  This is a recently 
validated measure to address the question of satisfactory repi[INVESTIGATOR_754325].  Other measures included in this study are the , , 
, DLQI (CDLQI), .  Relationships between improvement and 
VASI score improvements in the se parameters will be examined.  
2.2.2.  Justification for Dose  
The safety and efficacy outcomes from the Phase 2 study,  INCB  [ZIP_CODE] -211, can be summarized 
as follows:  
• All ruxolitinib cream treatment arms demonstrated efficacy and superiority over 
vehicle in F -VASI5 0 and F -VASI75 at Week 24 with a clear separation from vehicle 
emerging by [CONTACT_10585] 12.  
• At Week 24, 1.5% QD and BID treatment regimens further separate from the 0.15% 
and 0.5% treatment regimens with the highest response at Week 24 in F -VASI50 
(50.0%) in the 1 .5% QD regimen.  
• The 1.5% BID treatment regimen demonstrated the highest response for F -VASI75 at 
both Week 24 (30.3%) and Week 52 (51.5%).  T -VASI50 response in the 1.5% BID 
regimen was modest at Week 24 (12.1%); however, this regimen also demonstrated 
the highest response for T -VASI50 (36.4%) at Week 52, and it is recognized that 
repi[INVESTIGATOR_754326].  
• All ruxolitinib treatment arms were generally safe and well -tolerated with no 
significant TEAEs or applica tion site events and no clinically relevant hematological 
changes through Week 52.  
Based on the above data, the proposed treatment regimen of ruxolitinib cream for the Phase 3 
studies is 1.5% BID.  Limiting treatment to up to 10% BSA will limit exposure an d potentially 
improve the benefit -risk. 
2.3. Benefit/Risk Assessment  
In nonclinical studies, ruxolitinib cream did not act as a contact [CONTACT_754346], nor did it produce 
significant dermal irritation or demonstrate phototoxicity or photoallergenic potential.  The lack 
of adverse cutaneous effects has been supported by [CONTACT_427450], where cutaneous AEs 
have been infrequent and of similar frequency and severity as with vehicle control treatment.  
Long -term immune suppression may occur with JAK inhibition,  which could potentially increase 
the risk of cutaneous viral skin infections and nonmelanoma skin cancers.  Participants should be 
monitored accordingly.  

Incyte Corporation  Page [ADDRESS_1032411] hematology parameters (red 
blood cells and platelet counts) were noted in the laboratory assessments, they were mostly 
within the limits of the normal range of values, transient, asymptomatic, and cl inically 
insignificant and did not necessitate any remedial action.  
Currently, there are no approved therapi[INVESTIGATOR_312300], and treatments are empi[INVESTIGATOR_427415].  Current therapi[INVESTIGATOR_754327] y response, 
and there are limitations and safety concerns with long -term use of some therapi[INVESTIGATOR_014], including 
topi[INVESTIGATOR_427417].  Given the psychosocial burden and 
stigma that has been reported in this disease, patients  with vitiligo warrant access to new studies.  
In summary, ruxolitinib cream 1.5% BID can be safely used as a topi[INVESTIGATOR_427418] -to-risk ratio from among those 
investigated.  More detai led information about the known and expected benefits and risks and 
reasonably expected AEs of ruxolitinib cream may be found in the ruxolitinib cream IB. 
Incyte Corporation  Page 22 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  3. OBJECTIVES AND ENDPOINTS  
Table  4 presents the objectives and endpoints.  
Table  4: Objectives and Endpoints  
Objectives  Endpoints  
Primary  
To evaluate the duration of clinical response of 
ruxolitinib cream in participants with vitiligo.  For participants who are randomized in Cohort A:  
• Time to relapse (defined as < F -VASI75).  
Key Secondary  
To evaluate the duration of clinical response of 
ruxolitinib cream in participants with vitiligo.  For participants who are randomized in Cohort A:  
• Time to maintain ≥ F -VASI90 response.  
Secondary  
To further evaluate the efficacy of ruxolitinib 
cream.  • Proportion of participants who achieve 
F-VASI50/75/90  during the extension treatment 
period.  
• Actual measurements, change, and percentage 
change from baseline in F -VASI.  
• Proportion of participants who achieve 
T-VASI50/75/90 during the extension treatment 
period.  
• Actual measurements, change, and percentage 
change from baseline in T -VASI.  
• Actual measurements, change, and percentage 
change from baseline in F -BSA.  
• Actual measurements, change, and percentage 
change from baseline in T -BSA.  
• Proportion of participants achieving a VNS of 
“4 – A lot less noticeable” or “5 – No longer 
noticeable” during the extension treatment 
period.  
To determine the participants' quality of life  • Change from Week 52 in DLQI (or CDLQI) 
during the extension treatment period.  
To evaluate the safety and tolerability of 
ruxolitinib cream.  • The frequency and severity of AEs; includes 
performing physical examinations and 
collecting vital signs and laboratory data for 
hematology and serum chemistry.  
To evaluate the ruxolitinib PK in plasma after 
treatment with ruxolitinib cream.  • Trough plasma concentrations of ruxolitinib at 
Week 80 and Week 104.  
Incyte Corporation  Page 23 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  Table  4: Objectives and Endpoints (Continued)  
Objectives  Endpoints  

Incyte Corporation  Page [ADDRESS_1032412] completed either Study 
INCB  [ZIP_CODE] -306 or Study INCB  [ZIP_CODE] -307 (parent studies) in which the participants will have 
been using ruxolitinib cream 1.5% BID for the previous 28  to 52  weeks (depending on their 
initial randomization in the parent study;  see Figure  1). 
The p arent studies are randomized, vehicle -controlled studies in adolescent and adult participants 
(age ≥ 12 years) with non -segmental vitiligo who have depi[INVESTIGATOR_352829] ≥ 0.5% BSA 
on the face, ≥ 0.5 F -VASI, ≥ 3% BSA on nonfacial areas, and ≥ 3 T -VASI.  Total body involved 
vitiligo area (facial and nonfacial) was not to exceed 10% BSA.  Approximately 300 participants 
per each parent study were to be randomized 2:1 to receive an initial, double -blind study 
treatment of ruxolitinib cream 1.5% BID or vehicle (applied to depi[INVESTIGATOR_754328] 10% total BSA) for 24 weeks.  After completion of the Week  24 
assessments, participants in these studies were offered th e opportunity to receive an additional 
28 weeks of open -label treatment extension with ruxolitinib cream 1.5% BID under the parent 
study protocol.  
Participants who successfully complete the 52 -week treatment in either of the parent studies 
(ie, 52 weeks ruxolitinib cream or 24 weeks vehicle plus 28 weeks ruxolitinib cream)  and 
tolerated ruxolitinib treatment without safety concern and with good compliance for continuation 
may be eligible to participate in this treatment extension study.  
Visits in this treat ment extension study are named to reflect continuation from the parent studies, 
with the first visit of this treatment extension study occurring at Week 52.  The eligibility 
assessment for this extension study occurs at Week  52.  The treatment extension pe riod of this 
study comprises the period from the Week  52 visit to the Week  104 visit (inclusive).  Following 
the last application of study treatment at Week  104, there will be a [ADDRESS_1032413] experienced repi[INVESTIGATOR_754321], as well as to provide long -term efficacy and safety data in vitiligo patients, regardless 
of how quickly or completely they responded to treatme nt initially.  Eligible participants in this 
study will be assigned to 1 of 2 cohorts, Cohort  A or Cohort  B, based on their F -VASI responses 
at the time of enrollment in this study (ie,  at Week 52).  
Treatment in Cohort A is a randomized withdrawal design a nd will provide data on the duration 
of response following withdrawal of ruxolitinib cream and maintenance of response with its 
continued use.  Participants who achieve complete or almost complete facial repi[INVESTIGATOR_371] 
(ie, achieve ≥ F-VASI90) at Week 52 i n the parent study will be assigned to Cohort  A and will 
be stratified by [CONTACT_754342] 1 of the parent study and 
randomized 1:1 to treatment with vehicle cream BID or ruxolitinib cream 1.5%  BID for an 
additional 52  weeks (ie , until EOT at Week  104).  However, any participants in Cohort  A who 
Incyte Corporation  Page 25 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  experience relapse (defined as < F -VASI75) will receive ruxolitinib cream 1.5%  BID as an 
open -label rescue treatment until they complete treatment (Week  104 or EOT).  
Treatment in Cohort B  will provide long -term efficacy and safety data for ruxolitinib cream in 
vitiligo patients.  Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies 
will be assigned to Cohort  B and will continue ruxolitinib cream 1.5% BID for 52  week s 
(ie, until EOT Week  104).  
For Cohort  A, the participant, investigator, and sponsor will remain blinded to treatment 
assignment; the treatment for Cohort  B will be open -label.  
During this extension study, participants will receive study treatment (ruxolit inib cream 1.5% 
BID or vehicle) for 52 weeks to be applied to depi[INVESTIGATOR_754329]; the total 
treated areas (facial plus nonfacial areas) should not exceed 10% BSA.  Participants should 
continue to treat depi[INVESTIGATOR_754330] t reatment at baseline of the parent study even if 
the area begins to improve or fully repi[INVESTIGATOR_2517].  
Thus, depending on their initial randomized treatment in the parent study and the treatment to 
which they are randomized at Week  [ADDRESS_1032414] received 
ruxolitinib cream 1.5% BID for a minimum of 28 weeks and a maximum of 104 weeks.  
Safety endpoints, such as nature of AEs (type, frequency, and severity includes performing 
targeted physical examination and collecting vital sign s and routine laboratory investigations) 
will be monitored and recorded throughout the course of this study.  
4.2. Overall Study Duration  
Eligibility will be evaluated on the first day of this extension study, which occurs on the same 
day as the parent study Wee k 52 visit; the treatment extension period is 52 weeks; and safety 
follow -up is 30 days.  Total duration of this study is approximately 56 weeks ( see Figure  1). 
The study will begin when the first participant (or parent or guardian) signs the ICF.  The end of 
the study is defined as the date of the last visit of the last participant in the study or the date that 
the last participant di scontinued study drug and completed applicable safety follow -up 
assessments or is lost to follow -up.  A participant is considered to have completed the study if 
he/she has completed all study visits, including the safety follow -up visit.  
4.3. Study Termination  
The investigator retains the right to terminate study participation at any time, according to the 
terms specified in the study contract.  The investigator is to notify the IRB/IEC in writing of the 
study's completion or early termination, send a copy of th e notification to the sponsor or 
sponsor's designee, and retain 1  copy for the site study regulatory file.  
The sponsor may terminate the study electively or if required by [CONTACT_352931].  In the event 
of significant safety findings, the study will be t erminated.  If the study is terminated 
prematurely, the sponsor or designee will notify the investigators, the IRBs/IECs, and regulatory 
bodies of the decision and reason for termination of the study.  
Incyte Corporation  Page 26 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  5. STUDY POPULATION  
Deviations from eligibility criteria a re not allowed because they can potentially jeopardize the 
scientific integrity of the study, regulatory acceptability, and/or participant safety.  Therefore, 
adherence to the criteria as specified in the Protocol is essential.  Prospective approval of 
Protocol deviations to recruitment and enrollment criteria, also known as Protocol waivers or 
exemptions, are not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Currently enroll ed and receiving treatment in INCB  [ZIP_CODE] -306 or INCB [ZIP_CODE] -307 
studies evaluating ruxolitinib cream in participants with vitiligo.  
Note:  Eligibility criteria for INCB  [ADDRESS_1032415] be willing to take appropriate contraceptive measures  
to avoid pregnancy or fathering a child for the duration of study participation with the 
exception of the following:  
a. Females of non -childbearing potential (ie, or surgically sterile with a hysterectomy 
and/or bilateral oophorectomy OR postmenopausal, ≥ 12  months of amenorrhea 
without an alternative medical cause).  
b. Prepubescent adolescents (age 12 -18 years old at the time enrolled in parent studies).  
Note:  Information about specific types of acceptable contraceptive measures and 
duration of contraceptive u se are provided in  Appendix  B. 
6. For adult participant, ability to comprehend and willingness to sign an ICF; for 
adolescent participant,  written in formed consent of the parent(s) or legal guardian and 
written assent from the adolescent participant when possible.  
Note:  Adolescents, who during the course of the study become legal adults, will be asked 
for their consent to continue the study, and in th e event of lack thereof, will be 
discontinued from further participation.  
Incyte Corporation  Page 27 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  5.2. Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Has been permanently discontinued from study treatment in the parent study for any  
reason.  
2. Participants with an uncontrolled intercurrent illness or any concurrent condition that, in 
the investigator's opi[INVESTIGATOR_1649], would jeopardize the safety of the participant or compliance 
with the Protocol.  
Note:  See information provided in Exclusion C riterion 4 of the INCB  [ZIP_CODE] -306/ 
INCB  [ZIP_CODE] -307 parent study protocol ( Appendix  A); the investigator should consult 
with the sponsor medical monitor  if there are any questions regarding uncontrolled 
intercurrent illness or any concurrent condition that may be exclusionary.  
3. Pregnant or breastfeeding woman.  
4. Participants who live with anyone participating in any current Incyte -sponsored 
ruxolitinib cream  study.  
5.3. Lifestyle Considerations  
Participants should continue to avoid excessive exposure to artificial sunlight (including tanning 
booths, sun lamps, etc).  
If sunscreen, makeup, or other cosmetics have been applied to the areas to be treated, participants  
should follow the application guidance (see Section  6.6.1 ). 
It is recommended that swimming should not take place within [ADDRESS_1032416] 2 hours after shaving.  
5.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently entered in the study.  
5.5. Repla cement of Participants  
Participants will not be replaced during the study.  
Incyte Corporation  Page 28 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  6. STUDY TREATMENT  
See Appen dix D for COVID -19–related guidance.  
6.1. Study Treatments Administered  
Table  5 presents the study treatment information.  
Table  5: Study Treatment Information  
Study treatment name:  [CONTACT_352991]:  Cream  
Unit dose strength(s)/dosage 
level(s):  1.5%  Not applicable  
Route of administration:  Topi[INVESTIGATOR_352855]:  BID.  A thin film is applied to 
depi[INVESTIGATOR_352857].  BID.   A thin film is applied to the 
depi[INVESTIGATOR_352857].  
Packaging and labeling:  Ruxolitinib cream and vehicle cream will be provided in 60 g tube.  
Each tube will be labeled as required per country requirement.  
Storage:  Ambient (15°C -30°C/59°F -86°F)  
Status of treatment in 
participating countries:  Investigational  Not applicable  
On visit days, study drug will be applied in the clinic during the visit.  Participants should 
remove study drug from the tube in fingertip units until all of the areas to be treated are covered 
by a thin film; the tube will be weighed before and after application to determine the 
participant’s dosage.  On the day of a visit, the participant should not apply the study drug at 
home and will apply study drug from the new kit in t he clinic.  Participants will be instructed to 
document treated areas and be advised to limit use to no more than one [ADDRESS_1032417] the study site to discuss with the investigator whether additional 
evaluation at the clinic is required.  If any other skin products that are permitted under the study 
Protocol are used, participants should continue  these unchanged during the study.  
During the treatment extension period, participants should follow the below study drug 
application guidance:  
• All participants in Cohort A will use their randomly assigned treatment (either vehicle 
or ruxolitinib cream) on  both the face and total body.  
• Participants should apply study drug to depi[INVESTIGATOR_754331] a T -BSA 
(facial and nonfacial) of ≤  10% BSA.  
Incyte Corporation  Page 29 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  • Participants should continue to treat all depi[INVESTIGATOR_754332] ( Day 1 of the parent study) even if the area begins to improve or 
fully repi[INVESTIGATOR_2517].  
• Participants who have an expansion of existing areas of vitiligo or develop new 
vitiligo lesions during the course of the treatment extension period may treat these 
areas aft er a visit to document the VASI score and other measures of vitiligo (may be 
unscheduled visit), as long as the new treated T -BSA (facial and nonfacial) does not 
exceed 10% BSA.  Newly developi[INVESTIGATOR_754333].  The VASI  scores for these new lesions should not be calculated with or 
combined together with treated areas identified at baseline (Day1 of parent study).  
6.2. Preparation, Handling, and Accountability  
The investigator or designee must confirm and document that appropr iate temperature conditions 
(both ruxolitinib cream and vehicle cream are to be stored between 15°C and 30°C [59°F -86°F]) 
have been maintained during transit for all study treatments received and that any discrepancies 
are reported and resolved before use of the study treatment.  
Only participants enrolled in the study may receive study treatment, and only authorized site 
staff may supply study treatment.  Immediately after application of ruxolitinib cream, 
participants are to wash their hands thoroughly wit h soap and warm water (unless the area to be 
treated includes the hands).  Refer to the Study Pharmacy Manual for participant instructions for 
handling of study drug.  
All study treatment must be stored in a secure, environmentally controlled, and monitored  
(manual or automated) area in accordance with the labeled storage conditions, with access 
limited to the investigator and authorized site staff.  Participants should store study treatment at 
ambient temperature conditions.  
The investigator (or designee) i s responsible for study treatment accountability, reconciliation, 
and record maintenance (ie, receipt, reconciliation, and final disposition records).  Inventory and 
accountability records must be maintained and readily available for inspection by [CONTACT_43038] y 
monitor and are open to inspection at any time by [CONTACT_75478].  The 
investigator or designee must maintain records that document:  
• Delivery of study drug(s) to the study site.  
• Inventory of study drug(s) at the site.  
• Participant u se of the study drug(s) including tube counts from each supply 
dispensed.  
• Return of study drug(s) to the investigator or designee by [CONTACT_4317].  
The investigational product must be used only in accordance with the Protocol.  The investigator 
will also ma intain records adequately documenting that the participants were provided the 
specified study drug.  These records should include dates, quantities, and any available batch or 
serial numbers or unique code numbers assigned to the investigational product an d study 
participants.  
Incyte Corporation  Page [ADDRESS_1032418] and retain all used, unused, and partially used containers of study drug 
until verified by [CONTACT_11200] (unl ess otherwise agreed to by [CONTACT_456]).  At the 
conclusion of the study, the investigator or designee will oversee shipment of any remaining 
study drug back to the sponsor or its designee for destruction according to institutional SOPs.  If 
local procedur es mandate on -site destruction of investigational supply, the site should (where 
local procedures allow) maintain the investigational supply until the study monitor inspects the 
accountability records in order to evaluate compliance and accuracy of account ability by [CONTACT_198373].  At sites where the study drug is destroyed before monitor inspection, the 
monitors rely on documentation of destruction per the site SOP.  
Further guidance and information for the final disposition of unused study treatme nts are 
provided in the study materials provided to sites.  
6.3. Measures to Minimize Bias:  Randomization and Blinding  
All participants will be centrally assigned to study treatment using an IRT system.  For Cohort  A, 
the system will assign in a 1:1 ratio ( ruxolitinib cream 1.5% BID:vehicle).  For Cohort B, the 
system will assign all participants to ruxolitinib cream 1.5% BID.  
The IRT will track participant visits, randomize participants according to the defined parameters, 
maintain the blinding (Cohort  A on ly), and manage study drug inventory.  Full details will be 
provided in the IRT Manual.  Study treatment will be dispensed at the study visits summarized in 
the SoA (see Table  3). 
For Cohort  A, the participant, investigator, and sponsor will remain blinded to treatment 
assignment; the treatment for Cohort  B will be open -label.  After the database lock for the 
primary analysis (Week  104),  the participan t, the investigator, and the sponsor will be unblinded.  
6.4. Study Treatment Compliance  
Compliance with all study -related treatments must be emphasized to the participant by [CONTACT_89184], and appropriate steps should be taken to optimize compliance during  the study.  
Compliance with ruxolitinib cream will be evaluated by [CONTACT_4317]’ adherence to the 
application regimen and drug accountability documented by [CONTACT_352966]/designee (tube count s). 
In general, the application com pliance will be determined by [CONTACT_352937], which should be within 70% to 130% of the prescribed 
number of applications.  Participants will be instructed to bring all study drugs with them to the 
study visi ts in order for site personnel to conduct tube counts to assess study drug accountability.  
The drug accountability documentation will be used by [CONTACT_352967].  
Incyte Corporation  Page 31 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  6.5. Dose Modifications  
6.5.1.  Criteria and Procedures for Application Inte rruptions and Modifications of 
Study Drug  
Safety concerns should be discussed with the sponsor immediately upon occurrence or awareness 
to determine whether the participant should continue or discontinue study treatment.  
In some circumstances, it may be ne cessary to temporarily interrupt treatment with study drug 
(ruxolitinib cream or vehicle cream).  Except in cases of emergency, it is recommended that any 
findings of concern (eg, AE) be confirmed and that the investigator consult with the sponsor 
medical monitor (or other representative of the sponsor) before interrupting study drug.  
Additionally, the investigator must obtain approval from the sponsor before restarting study 
drug.  Participants who experience a recurrence of the initial AEs upon restartin g the study drug 
and the AE is confirmed related to the study drug may need the study drug to be permanently 
discontinued.  
Instructions for application interruptions of study treatment are outlined in Table  6.  Individual 
decisions regarding interruptions should be made using clinical judgment in consultation with the 
medical monitor (whenever possible), taking into account relatedness of the AE to the stu dy drug 
and the participant's underlying condition.  
Table  6: Guidelines for Interruption and Restarting of Study Drug  
Adverse Event  Action Taken  
Chemistry  
ALT (> 3 × ULN) or AST (> 3 × ULN)  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible 
and immediate delivery of the laboratory results 
requested.  
• Study drug applications must be interrupted.  At the 
discretion of the investigator, after consultation with 
the sponsor, study drug application may be restored 
once these have resolved.  
Other laboratory abnormalities  
Any other Grade 3 laboratory abnormality, 
with the exception of asymptomatic 
elevations in triglyceride, cholesterol, or 
amylase  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible 
and immediate delivery of the laboratory results 
requested.  
• Study drug applications must be interrupted.  At the 
discretion of the investigator, after consultation with 
the sponsor, study drug application may be restored 
once these have resolved.  
Any Grade [ADDRESS_1032419] 
or ALT (> 5 × ULN)  • Laboratory abnormalities should be confirmed with 
repeat testing within 48 hours whenever possible 
and immediate delivery of the laboratory results 
requested.  
• Discontinue study drug if lab abnormalities are 
confirmed.  
Incyte Corporation  Page 32 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  6.5.2.  Criteria for Permanent Discontinuation of Study Drug  
The occurrence of unacceptable severity of an AE not caused by [CONTACT_352968].  Unacceptable severity is defined as follows:  
• Occurrence of an AE that is related to treatment with the study drug that, in the 
judgment of the investigator o r the sponsor's medical monitor, compromises the 
participant's ability to continue study -specific procedures, or continuing treatment is 
considered to not be in the participant's best interest.  
• Worsening of vitiligo that requires treatment with a prohibite d concomitant 
medication.  
See Section  7 for discontinuation procedures.  
6.6. Concomitant Medications and Procedures  
All concomitant medications and treatments (including over -the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be reviewed at each study visit.  
Any concomitant medication/treatment received from the first dose of study treatment in this 
extension s tudy through [ADDRESS_1032420] dose of study treatment will be recorded in the 
eCRF.  Any addition, deletion, or change in the dose of these medications will also be recorded.  
Concomitant treatments/procedures that are required to manage a participan t's medical condition 
during the study will also be recorded in the eCRF.  The medical monitor should be contact[CONTACT_754347].  
6.6.1.  Permitted Medications and Procedures  
The following are permitted during the study w ith application guidance.  Investigators and site 
staff are expected to use their best clinical judgement with these recommendations and adhere to 
the guidelines as closely as possible.  The sponsor should be consulted if there are specific 
questions.  
• Participants may use bland emollients or camouflage makeup.  
Note:  Emollients or camouflage makeup should not be used within [ADDRESS_1032421] then be washed off and the 
skin dried before application of the study drug.  
• If sunscreen is needed, a mineral -based sunscreen (such as zinc  oxide – or 
titanium  oxide –based ) with SPF of at least [ADDRESS_1032422] 2 hours after study 
drug application.  
Note:  Sunscreen must be carefully removed from the skin before study drug 
application if it has been applied to the areas to be treated.  
• Study drug should be applied at l east 2 hours after shaving.  
• Concomitant oral vitamins and other skin products should be approved by [CONTACT_427456].  
Incyte Corporation  Page 33 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  6.6.2.  Restricted Medications and Procedures  
The following are restricted during the study unde r specified conditions:  
• Use of any over -the-counter, nonprescription preparations (including vitamins, 
minerals, and phytotherapeutic, herbal, or plant -derived preparations) from the time 
of the Week  52 visit through the safety follow -up visit, unless deem ed acceptable by 
[CONTACT_093].  
• Use of any prescription medication (including immunizations, phytotherapeutic, 
herbal, or plant -derived preparations) from the time of the Week  52 visit through the 
safety follow -up visit, unless deemed acceptable by [CONTACT_093].  
• Participants should not take baths or showers within 2 hours after study drug 
application.  
• Treatment for dermatologic disease besides vitiligo (eg, AD or psoriasis) is allowed 
for areas not being treated for vitiligo:  
− It involves < 10% of the  BSA outside of the areas treated for vitiligo.  
− Topi[INVESTIGATOR_22777], pi[INVESTIGATOR_031], or corticosteroids Class 6 or 7 (or low potency 
per WHO classification; see Appendix  C) are at a stable dose.  
− Topi[INVESTIGATOR_427435] 1 through 5 (see Appendix  C) are used for no longer 
than 7 sequential days and n o more than 14 days in total.  
• Use of oral corticosteroids for no longer than 7 days if deemed acceptable by [CONTACT_427457] (eg, asthma 
exacerbation, bronchitis).  
6.6.3.  Prohibited Medications and Procedures  
Participants should not use any other treatments for vitiligo at any time during the study.  The 
following medications are not permitted during the study:  
• Any investigational medication other than the study drugs.  
• Treatment known to affect the course of vi tiligo, such as skin bleaching treatments 
(eg, hydroquinone) or depi[INVESTIGATOR_6164] (eg, monobenzone)  
Note:  Skin bleaching (eg, hydroquinone) use is prohibited during the study but is 
allowed as prior therapy.  
• Other topi[INVESTIGATOR_12450] (except those in Section  6.6.1 ) or treatments for vitiligo 
(including corticosteroids [topi[INVESTIGATOR_2855], systemic, or oral], vitamin D derivatives, 
calcineurin inhibitors, laser or s urgical treatments, phototherapy, or other procedures).  
• Biological therapi[INVESTIGATOR_427436].  
• Any phototherapy, including tanning beds.  
• Live or live -attenuated vaccination.  
Incyte Corporation  Page 34 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  6.7. Rescue Treatment  
For participants in Cohort A, if there is a loss  of clinically meaningful response on the face 
(ie, < F-VASI75) at any time, the participants will receive open -label ruxolitinib cream 1.5% 
BID until completing the study (ie, Week 104 or EOT).  
6.8. Treatment After the End of the Study  
No treatment will be pro vided to participants after the end of the study.  
7. DISCONTINUATION OF S TUDY TREATMENT AND 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL  
7.1. Discontinuation of Study Treatment  
7.1.1.  Reasons for Discontinuation  
Participants must  be discontinuation from study treatment for the  following reasons:  
• A participant is found not to have met eligibility criteria (any exclusion criterion or 
any inclusion criteria related to participant safety) or if legal requirements have been 
violated.  
• The participant becomes pregnant.  
• Consent is with drawn.  
Note :  Consent withdrawn means that the participant has explicitly indicated that they 
do not want to be followed any longer; in this case no further data, except data in 
public domain, may be solicited from or collected on the participant.  Partici pants 
may choose to discontinue study treatment and remain in the study for safety 
monitoring.  
• Further participation would be injurious to the participant's health or well -being, in 
the investigator's medical judgment.  
• Any AE of unacceptable severity as no ted in Section  6.5.2 . 
• The study is terminated by [CONTACT_456].  
• The study is terminated by [CONTACT_19407], IRB, or IEC.  
A participant  may be discontinued from study treatment as follows:  
• If, at 2 consecutive study visits, a participant's drug usage exceeds one 60 g tube per 
week.  
• If a participant is noncompliant with study procedures or study drug administration in 
the investigator's op inion, the medical monitor should be consulted for instruction on 
handling the participant.  
Incyte Corporation  Page [ADDRESS_1032423] dos e of 
study treatment and the reason for discontinuation of study treatment will be recorded in the 
eCRF.  
If a participant is discontinued from study treatment:  
• The study monitor or sponsor must be notified.  
• The reason(s) for withdrawal must be documented in the participant's medical record 
and the primary reason for withdrawal must be included in the eCRF.  
• The EOT visit should be performed.  
• The date of the EOT visit should be recorded in the eCRF.  
• Participants must be followed for safety until the time of the safety follow -up visit or 
until study treatment –related AEs resolve, return to baseline, or are deemed 
irreversible, whichever is longest.  
If the participant discontinues study treatment and actively withdraws consent for collection of 
follow -up data ( safety follow -up or disease assessment), then no additional data collection 
should occur; however, participants will have the option of withdrawing consent for study 
treatment but continuing in the safety follow -up period of the study for safety/efficacy 
assessments.  
7.2. Participant Withdrawal From the Study  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reas ons. 
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
See Table  [ADDRESS_1032424] to follow -up if he/she repeatedly fails to return for 
scheduled visits and is unable to be cont acted by [CONTACT_3452].  
Incyte Corporation  Page [ADDRESS_1032425] be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact [CONTACT_14315].  The participant will be counseled regarding the importance of 
maintaining the assigned visit schedule, and the site will ascertain whether or not the 
participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investiga tor or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary, a certified letter to the participant's last known mailing address 
or local equivalent methods).  These contact [CONTACT_754348]'s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up. 
8. STUDY ASSESSMENTS AN D PROCEDURES  
See Appendix  D for COVID -19–related guidance.  
8.1. Administrative and General Procedures  
8.1.1.  Informed Consent Process  
• The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions 
regarding the study.  
− Informed consent/assent must be obtained before any study -related procedures are 
conducted, unless otherwise specified by [CONTACT_760].  
Note:  Adolescent participants who become legal adults during the study will be 
asked for their signed consent to continue the study, and in the event of lack 
thereof, will be discontinued from further participation.  
− Informed consent/assent m ust be obtained using the IRB/IEC -approved version in 
a language that is native and understandable to the participant.  A template will be 
provided by [CONTACT_3552].  The sponsor or its designee must review 
and acknowledge the site -specific c hanges to the ICF/assent template.  The 
ICF/assent must include a statement that the sponsor or its designee and 
regulatory authorities have direct access to participant records.  
− The ICF/assent must contain all required elements and describe the nature, sc ope, 
and possible consequences of the study in a form understandable to the study 
participant.  
• Participants must be informed that their participation is voluntary.  Participants or 
their legally authorized representative will be required to sign a statemen t of informed 
Incyte Corporation  Page 37 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  consent that meets the applicable requirements and regulations for the country in 
which the study is being conducted as well as the IRB/IEC or study center.  
• The participant must be informed that his/her personal study -related data will be used 
by [CONTACT_89192].  The level of disclosure 
must also be explained to the participant.  
• The participant must be informed that his/her medical records may be examined by 
[CONTACT_754349] o ther authorized personnel appointed by [CONTACT_103], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in  the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must 
also sign the ICF.  
• Participants must provide consent to the most current version of the ICF(s) during 
their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant's legally 
authorized representative.  
8.1.2.  Eligibility Procedures  
All information associated with eligibility requirements must be entered into the appropriate 
eCRF pages.  
Results from the eligibility assessments will be reviewed by [CONTACT_754350].  
8.1.3.  Interactive Response Technology Procedure  
Each participant will be identified in the study by a participa nt ID number, which is a 
combination of the site ID and participant number; this will be the same participant ID number as 
assigned in the parent study.  Upon determining that the participant is eligible for study entry, the 
IRT system will be contact[CONTACT_754351].  Additionally, the 
IRT system will be contact[CONTACT_352971].  
Additional details are provided in the IRT Manual.  
8.1.4.  Distribution of Reminder Cards and Diaries  
Startin g at the Week  52 visit and each visit thereafter, a study drug –specific diary will be given 
to each participant in order to record use of the study drug.  The completed diary will be 
collected during each of the participant's visits.  
Qualified clinical sit e staff will review the participants' entries for compliance.  Participants who 
are noncompliant with their study drug schedule (defined as < 70% or > 130% of the expected 
number of applications between study visits) will have their administration instruct ions 
reinforced by [CONTACT_1720] a qualified designee.  Participants will be considered compliant 
with the treatment regimen if they apply at least 70% but no more than 130% of the expected 
applications during participation in the treatment period of  the study.  
Incyte Corporation  Page [ADDRESS_1032426] starting on Week  52 and at all visits (through 
Week  92).  The reminder card will indicate the date/time of the next visit and will also remind 
the participant that they should have their applic ation at the clinic during the visit under site 
supervision after their blood draws for PK and safety evaluations have been completed.  
8.2. Efficacy Assessments  
8.2.1.  Body Surface Area  
Facial % BSA and total % BSA (includes facial and nonfacial areas) depi[INVESTIGATOR_754334].  Body surface area assessment will be performed by [CONTACT_754352].  BSA should be estimated to the nearest 0.1%.  The approximate size of the 
participant’s entire palmar surface (ie, the palm plus 5 digits) shou ld be considered as 1% BSA, 
and the approximate size of the participant’s thumb should be considered as 0.1% BSA.  
8.2.2.  Vitiligo Area Scoring Index  
Areas affected by [CONTACT_61911][INVESTIGATOR_352863].  It is based on 
a composite esti mate of the overall area of vitiligo patches at baseline and the degree of macular 
repi[INVESTIGATOR_312316].  
Facial VASI  is measured by [CONTACT_352943] (% of BSA) and the degree of 
depi[INVESTIGATOR_371].  The percentage of BSA (hand unit) vitiligo involvement is estimated by [CONTACT_352944] (see Section  8.2.1 ).  Hand unit is based on participan t’s 
hand size.  Investigator uses his/her hand to mimic the participant’s hand size to evaluate 
percentage of BSA vitiligo involvement.  The degree of depi[INVESTIGATOR_754335]:  0, 
10%, 25%, 50%, 75%, 90%, or 100%.  At 100% depi[INVESTIGATOR_371], no pi[INVESTIGATOR_352865]; at 90%, 
specks of pi[INVESTIGATOR_352866]; at 75%, the depi[INVESTIGATOR_352867]; at 
50%, the depi[INVESTIGATOR_352868]; at  25%, the pi[INVESTIGATOR_352911]; at 10%, only specks of depi[INVESTIGATOR_352871].  The F -VASI is then 
derived by [CONTACT_754353] (possible 
range 0 -3). 
The area "Face" is defined as including the area on the forehead to the original hairline, on 
the cheek vertically to the jawline and laterally from the corner of the mouth to the tragus .  
The area "Face" will not include surface area of the lips, scalp, ears, or neck but will 
include the nose and eyelids.  
Total body VASI  is calculated using a formula that includes contributions from all body regions 
(possible range,  0-100).  
VASI = Σ [han d units] × [Residual Depi[INVESTIGATOR_371]] all body sites  
The body is divided into the following 6 separate and mutually exclusive sites:  (1) head/neck, 
(2) hands, (3) upper extremities (excluding hands), (4) trunk, (5) lower extremities (excluding 
feet), and ( 6) feet.  The percentage of vitiligo involvement is estimated in hand units (% of BSA) 
by [CONTACT_312357].  Hand unit is based on 
participant’s hand size.  The investigator uses his/her hand to mimic the particip ant’s hand size to 
Incyte Corporation  Page 39 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  evaluate % BSA vitiligo involvement.  The degree of depi[INVESTIGATOR_312317]:  0, 10%, 25%, 50%, 75%, 
90%, or 100%.  The T -VASI is then derived by [CONTACT_754354] ( Hamzavi et al 2004 ). 
Full details will be provided in the Stu dy Manual.  
8.2.5.  Photography  
Photography of the face and/or body areas affected with vitiligo will be obtained at visits listed 
in Table  3. 

Incyte Corporation  Page 40 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  All sites will use 2D photography, and selected sites will also use 3D photography, to 
photograph areas of the participant’s face affected with vitiligo.  2D photography will be used at 
all sites for the target nonfacial depi[INVESTIGATOR_312320].  
Target nonfacial vitiligo depi[INVESTIGATOR_352881]:   At the baseline visit (Day  1) of the 
parent study (INCB  [ZIP_CODE] -306 or INCB [ZIP_CODE] -307), depi[INVESTIGATOR_754336]'s overall disease and that are to be treated with study drug will 
have been selected as targeted nonfacial vitiligo depi[INVESTIGATOR_312294].  These same areas will be 
assessed, measured, and documented in the participant's medical record at each visit of t his 
treatment extension study (see Table  3).  The genitalia area should not be photographed.  
Ad hoc photography of skin -related AEs is recommended.  
Photographic procedures will be standardized, and a full description of the methodology will be 
provided in a photography manual to be provided to the sites.  
8.2.6.  Patient -Reported Outcomes  
Quality of life will be assessed (see Table  3) using the following tools:  
• VNS (Section  [IP_ADDRESS] ); 
  
  
  
• DLQI/CDLQI (Section  [IP_ADDRESS] ); 
  
  
In order to avoid bias in the participants' responses to the questionnaires, all these assessments 
should be completed before any other evaluations or study procedures on the day of the study 
visit and before dis cussions with the investigator or study site staff.  
[IP_ADDRESS].  Vitiligo Noticeability Scale  
The VNS is a patient‐reported measure of vitiligo treatment success, which has a 5 -point scale 
(Batchelor et al 2016 ).  The baseline facial photograph from the parent study (INCB  [ZIP_CODE] -306 
or INCB  [ZIP_CODE] -307) will be shown to the participants for reference and a mirror will be 
provided for the participants to assess the vitiligo on their face.  The participant will be asked to 
respond to  the following query:  
Compared with before treatment, how noticeable is the vitiligo now?  Responses:  (1) More 
noticeable, (2) As noticeable, (3) Slightly less noticeable, (4) A lot less noticeable, and 
(5) No longer noticeable.  
VNS scores of 4 or 5 can b e interpreted as representing treatment success.  

Incyte Corporation  Page 41 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  [IP_ADDRESS].  Dermatology Life Quality Index  
The DLQI is a simple, 10 -questi on validated questionnaire to measure how much the skin 
problem has affected the participant over the previous 7 days ( Finlay and Khan 1994 ).  
Participants age ≥ 16 years will answer the questionnaire with (1) very m uch, (2) a lot, (3) a 
little, or (4) not at all.  
The questionnaire is analyzed under 6 headings as follows:  
• Symptoms and feelings (Questions 1 and 2);  
• Daily activities (Questions 3 and 4);  
• Leisure (Questions 5 and 6);  
• Work and school (Question 7);  

Incyte Corporation  Page 42 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  • Personal  relations (Questions 8 and 9);  
• Treatment (Question 10).  
CDLQI is the youth/children’s version of the DLQI.  For participants who are age <  16 years at 
baseline (Day 1) of the parent study (INCB  [ZIP_CODE] -306 or INCB [ZIP_CODE] -307), the CDLQI will be 
completed ins tead of the DLQI throughout their participation in this extension study.  This 
questionnaire is self -explanatory and can be simply given to the participant who is asked to fill it 
in and who may ask the help of the parent or guardian.  The questionnaire is  analyzed under 
6 headings as follows:  
• Symptoms and feelings (Questions 1 and 2);  
• Leisure (Questions 4, 5, and 6);  
• School or holidays (Question 7);  
• Personal relationships (Questions 3 and 8);  
• Sleep (Question 9);  
• Treatment (Question 10).  
Full details will be provided in the Study Manual.  
Full details will be provided in the Study Manual.  
8.3. Safety Assessments  
Planned timepoints for all safety assessment s are provided in the SoA ( Table  3). 
See Section  6.[ADDRESS_1032427] udy treatment.  Adverse events that begin or worsen after 
informed consent should be recorded on the Adverse Event Form in the eCRF regardless of the 
assumption of a causal relationship with the study drug.  Adverse events (including laboratory 
abnormaliti es that constitute AEs) should be described using a diagnosis whenever possible 
rather than by [CONTACT_147108].  
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant 's legally authorized representative).  The investigator and any 
qualified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following -up on AEs that are serious, 
considered related to the study treatment, or that caused the participant to discontinue the study 
treatment.  Care will be taken not to introduce bias when detecting AEs and/or SAEs.  
Open -ended and nonleading verbal questioning of the participant, such a s "How are you 
feeling?" is the preferred method to inquire about AE occurrences.  Adverse events may also be 
detected when they are volunteered by [CONTACT_754355], laboratory tests, or other assessments.  Th e definition, reporting, and recording 
requirements for AEs are described in Section  9. 
The investigator will submit any updated SAE data to the s ponsor immediately, without undue 
delay, under no circumstances later than 24 hours following knowledge of the event.  
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). 
8.3.2.  Physical Examinations  
Physical examinations will be conducted at the timepoints listed in Table  3. 
A comprehensive physical examination will include height and body weight and assessment of 
the following organ or body systems:  skin; head, eyes, ears, nose, and throat; thyroid; lungs; 
cardiovascular system; abdomen (liver, spleen); extremities; and lymph nodes.  A brief 
neurological examination  will also be performed.  
A targeted physical examination should be conducted as indicated by [CONTACT_312361], AEs, or other findings.  Abnormalities that are considered clinically significant in the 
judgment of the investigator are to be reported as AEs.  
Physical examinations must be performed by a medically qualified individual such as a licensed 
physician, physician's assistant, or an advanced registered nurse practitioner, as local law 
permits.  
8.3.3.  Vital Signs  
Vital sign measurements inc lude blood pressure, pulse, respi[INVESTIGATOR_697], and body temperature.  
Blood pressure and pulse will be taken with the participant in the recumbent, semi -recumbent, or 
sitting position after [ADDRESS_1032428].  Any abnormalities that are considered clinicall y 
significant in the judgment of the investigator are to be reported as AEs.  
Incyte Corporation  Page 44 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  8.3.4.  Laboratory Assessments  
Required laboratory tests are listed in Table  9, which include serum chemistry, hematology, and 
pregnancy testing (see Table  3 for timing of laboratory assessments).  Clinical laboratory tests 
will be performed at a central laboratory (refer to the Laboratory Manual for sample handling 
and shippi[INVESTIGATOR_3931]).  
Clinically significant abnormal laboratory findings are those that are not associated with the 
underlying disease, unless judged by [CONTACT_754356]'s condition.  All laboratory tests with values considered clinically significantly 
abnormal during participation in the study, or within [ADDRESS_1032429] dose of study 
treatment, should be  repeated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_10982].  
See Section  9.1 for information regarding laboratory abnormalities that should be recorded as an 
AE in the eCRF.  
Table  9: Required Laboratory Analytes  
Serum Chemistriesa Hematology  Pregnancy Testing  
Albumin  
Alkaline phosphatase  
ALT  
AST  
Bicarbonate or CO [ADDRESS_1032430] bilirubin (if total bilirubin is 
elevated above ULN)  
Total protein  Complete blood count, including:  
• Hemoglobin  
• Hematocrit  
• MCV  
• Platelet count  
• Mean platelet volume  
• Red blood cell count  
• Reticulocyte count  
• White blood cell count  
 
Differential count, including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  Female participants of childbearing 
potential have a serum test at 
Week  [ADDRESS_1032431].  
Note:  Additional tests may be required, as agreed upon by [CONTACT_86206], based on emerging safety data.  
a All serum chemistries will be pe rformed on samples collected without respect to food intake (ie, nonfasting).  
[IP_ADDRESS].  Pregnancy Testing  
A serum pregnancy test will be required for all women of childbearing potential during the 
Week  52 visit and at the safety follow -up visit (30 [+ 7] days after EOT).  Urine pregnancy tests 
will be conducted as outlined in Table  3, as medically indicated, or per country -specific 
requirement.  Urine pregnancy tests will be performed locally.  If a urine pregnancy test is 
positive, the results should be confirmed with a serum pregnancy test, which may be performed 
locally.  
Incyte Corporation  Page [ADDRESS_1032432] was positive, the investigator will assess 
the potential benefit/risk to the participant and determine whether it is in the participant's best 
interest to resume study drug and continue participation in the study.  
If a pregnancy is confirmed by a serum pregnancy test, see Section  9.[ADDRESS_1032433] application of 
study drug preceding the blood draw (if applicable) will be recorded in the eC RF. 
Instructions for sample preparation and shippi[INVESTIGATOR_352884].  
Participants will receive reminder cards in advance of the study visit providing instruction to 
hold the application of study drug on the day of the visit and a place to record the time of the 
prior dose of study drug.  
Pharmacokinetic blood samples can be collected at any time prior to study drug application at the 
site at the Week 80 visit and at any time at the W104 (EOT) visit.  Blood samples must not be 
draw n from the area that has been treated with study drug.  If it is not possible to access an area 
that is not treated with study drug, the site must adequately document this in the eCRF and not 
take the PK blood sample for that visit.  After the PK sample is  drawn, participants will apply 
ruxolitinib cream 1.5% or vehicle cream at the site.  
All analyses will be conducted by [CONTACT_109912] (Wilmington, DE) or Incyte's designee.  
8.6. Unscheduled Visits  
Unscheduled visits may occur at any time at the investigator's discretion, and appropriate clinical 
and laboratory tests may be performed, as clinically indicated.  
8.7. End of Treatment and/or Early Termination  
If a decision is made that the participant will permanently discontinue study drug, whether the 
participant is terminating the study early or the participant has completed the study, the EOT 
visit should be conducted.  If the EOT visit coincides with a regular study visit, then the EOT 
evaluations will supersede those of that scheduled vi sit, and the data should be entered in the 
EOT page in the eCRF.  If this decision does not coincide with a regular visit, reasonable efforts 
should be made to have the participant return to the site to have the EOT procedures completed.  

Incyte Corporation  Page 46 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  8.8. Safety Follow -Up 
The safety follow -up period is the interval between the EOT visit and the scheduled safety 
follow -up visit, which should occur 30  (+ 7) days after the EOT visit (or after the last dose of 
study drug if an EOT visit was not performed).  
Adverse events and SAE s must be reported up until at least [ADDRESS_1032434] the 
participant return for the safety follow -up visit and report any AEs that may occur during this 
period.  
9. ADVERSE EVENTS:  DEF INITIONS AND PROCEDU RES FOR 
RECORDING, EVALUATIN G, FOLLOW -UP, AND RE PORTING  
9.1. Definition of Adverse Event  
Adverse Event Defin ition  
• An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or 
not considered drug -related.  
• An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the use of study 
treatment.  
Events Meeting  the Adverse Event Definition  
• Any safety assessments (eg, ECG, vital signs measurements), including those that worsen from 
baseline, considered clinically significa nt in the medical and scientific judgment of the investigator 
(ie, not related to progression of underlying disease).  
• Abnormal laboratory test results constitute an AE if they are considered clinically meaningful, induce 
clinical signs or symptoms, require  concomitant therapy, or require changes in study drug.  
Whenever possible, a diagnosis (eg, anemia, thrombocytopenia) should be recorded in the eCRF 
rather than the abnormal lab result (eg, low hemoglobin, platelet count decreased).  
• Exacerbation of a chro nic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study treatment administration even though it may have 
been present before the start of the s tudy.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study treatment or a 
concomitant medication.  Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self -harming intent.  Such overdoses should be 
reported regardless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be reported as an 
AE or SAE.  Such instances will be captured in the efficacy assessments.  However, the signs, 
symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if 
they fulfill the definition of an AE or SAE.   
Incyte Corporation  Page 47 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  Events NOT  Meeti ng the Adverse Event Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by [CONTACT_754357]'s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant's condition or 
considered to be treatment -related by [CONTACT_1188]. 
• Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that leads to the 
procedure is the AE if it occurred after signing the ICF.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admissio n to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at 
the start of the study that do not worsen.  
9.2. Definition of Serious Adverse Event  
If an event is not an AE per the definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due 
to progression of disease).  
A Serious Adverse Event is defined as any untoward medical occurrence that, at any dose:  
a.  Resu lts in death  
b.  Is life -threatening  
The term "life -threatening" in the definition of "serious" refers to an adverse drug experience that 
places the participant, in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse 
experience a s it occurred.  This does not include an adverse drug experience that, had it occurred in a 
more severe form, might have caused death.  
c.  Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_19949] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would not have 
been appropriate in the physician's office or  outpatient setting.  Complications that occur during 
hospi[INVESTIGATOR_1084].  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious.  When in doubt as to whether "hospi[INVESTIGATOR_059]" occurred or was necessar y, the AE 
should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from baseline is 
not considered an AE.  
d.  Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person's ability to conduct normal life 
functions.  
• This definition is not intended to include experiences of relatively minor medical significance, such 
as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accid ental trauma 
(eg, sprained ankle), that may interfere with or prevent everyday life functions but do not constitute a 
substantial disruption.  
e.  Is a congenital anomaly/birth defect  
Incyte Corporation  Page 48 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  f. Other situations (Important Medical Event)  
An event that may not result in  death, be immediately life -threatening, or require hospi[INVESTIGATOR_059], but 
may be considered serious when, based on appropriate medical judgment, the event may jeopardize the 
participant and may require medical or surgical intervention to prevent one of the outcomes listed in 
the above definition.   Examples of such events include invasive or malignant cancers (excluding the 
disease[s] under study in oncology protocols), intensive treatment in an emergency department or at 
home for allergic bronchospasm, blood  dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_059], 
or development of drug dependency or drug abuse.  
9.3. Recording and Follow -Up of Adverse Events and/or Serious Adverse 
Events  
Adverse Event and Serious Adverse Event Recording  
• An AE/SAE that begins or worsens after informed consent is signed should be recorded on the 
Adverse Event Form in the eCRF.  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation 
(eg, hospi[INVESTIGATOR_1088], laboratory reports, a nd diagnostics reports) related to the event.  
• The investigator (or delegate) will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]'s medical records in 
lieu of complet ing the AE eCRF page.  
• There may be instances when copi[INVESTIGATOR_63475].  In this case, 
all participant identifiers, with the exception of the participant number, will be redacted on the copi[INVESTIGATOR_754337].  
• The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information.  Whenever possible, the diagnosis (not the individual signs/symptoms) 
will be documented as the AE/SAE.  When a  clear diagnosis cannot be identified, each sign or 
symptom should be reported as a separate AE/SAE.  
To the extent possible, each AE/SAE should be evaluated to determine:  
• The severity grade (CTCAE Grade 1 to 5).  See below for further instructions on the a ssessment of 
intensity.  
• Whether there is at least a reasonable possibility that the AE is related to the study drug:  suspected 
(yes) or not suspected (no).  See below for further instructions on the assessment of causality.  
• The start and end dates, unless  unresolved at final safety follow -up. 
• The action taken with regard to study drug as a result of the AE/SAE(s).  
• The event outcome (eg, not recovered/not resolved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown).  
• The seriousness, as per the SAE definition provided in Section  9.2. 
• The action taken with regard to the event.  Note:  If an AE is treated with a co ncomitant medication 
or nondrug therapy, this action should be recorded on Adverse Event Form, and the treatment should 
be specified on the appropriate eCRF (eg, Concomitant Medications, Procedures and Non -Drug 
Therapy).  
Incyte Corporation  Page 49 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0 Grades 1 through 5.  If an event is not 
classified by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate the 
grade of severity.  
The investigator will make an assessment of  intensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories:  
• Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment 
not indicated.  
• Grade 2:   Moderate; minimal, local, or noninvasive treatment indicated; limiting age appropriate 
activities of daily living.  
• Grade 3:   Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care activities of daily living.  
• Grade 4:   Life-threatening consequences; urgent treatment indica ted. 
• Grade 5:   Fatal.  
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment and each occurrence 
of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or  arguments 
to suggest a causal relationship, rather than that a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• The investigator will also consult the RSI in the ruxolitinib cream  IB in his/her assessment.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well 
as the temporal relationship of the event to study treatment administration, will be considered and 
investigated.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causality.  
• With regard to assessing causality of SAEs:  
− There may be situations in which an SAE has occur red and the investigator has minimal 
information to include in the initial report to the sponsor or designee.  However, it is very 
important that the investigator always make an assessment of causality for every event 
before the initial transmission of the  SAE data to the sponsor or designee . 
− The investigator may change his/her opi[INVESTIGATOR_9242] -up information and 
send a follow -up SAE report with the updated causality assessment.  
Follow -Up of Adverse Events and Serious Adverse Events  
• The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_754358]/or causality of the AE/SAE as fully as possib le.  This may include additional laboratory 
tests or investigations, histopathological examinations, or consultation with other healthcare 
professionals.  
• If a participant dies during participation in the study or during a recognized safety follow -up period , 
the investigator will provide the sponsor or designee with a copy of any postmortem findings, 
including histopathology.  
• New or updated information will be recorded in the originally completed eCRF.  
Incyte Corporation  Page 50 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  • Any updated SAE data will be submitted to the sponsor or  designee immediately, without undue 
delay, under no circumstances later than 24 hours following knowledge of the event.  
• Once an AE is detected, it should be followed until it has resolved or until it is judged to be 
permanent; assessment should be made at  each visit (or more frequently if necessary) of any changes 
in severity, the suspected relationship to the study drug, the interventions required to treat the event, 
and the outcome.  
• When the severity of an AE changes over time for a reporting period (eg,  between visits), each 
change in severity will be reported as a separate AE until the event resolves.  
9.4. Reporting of Serious Adverse Events  
Regardless of suspected causality (eg, relationship to study drug or study procedure[s]), all SAEs 
occurring after the participant has signed the ICF through the last study visit (or [ADDRESS_1032435] dose of study treatment, whichever occurs later) m ust be reported to the sponsor (or 
designee) immediately, without undue delay, under no circumstances later than 24 hours 
following knowledge of the event . 
Investigators are not obligated to actively seek AE or SAE information after conclusion of the 
study  participation.  However, if the investigator learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers it is at least 
reasonably possible that the event is related to the study treatment  or study participation, then the 
investigator must notify the sponsor (or designee) immediately, without undue delay, under no 
circumstances later than 24 hours following knowledge of the event . 
After the initial AE/SAE report, the investigator is require d to proactively follow each participant 
at subsequent visits/contacts.  All SAEs will be followed until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). 
Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
treatment under clinical investigation are met.  
If the SAE is not documented in the  ruxolitinib cream  IB for the study drug (new occurrence) 
and is thought to be related to the sponsor's stu dy drug, the sponsor or its designee may urgently 
require further information from the investigator for reporting to health authorities.  The sponsor 
or its designee may need to issue an Investigator Notification to inform all investigators involved 
in any  study with the same drug that this SAE has been reported.  Suspected Unexpected Serious 
Adverse Reactions will be collected and reported to the competent authorities and relevant ethics 
committees in accordance with Directive 2001/20/EC, or as per nationa l regulatory requirements 
in participating countries.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation.  The 
sponsor will c omply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC, and investigators.  
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.  
Incyte Corporation  Page 51 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  An investigator who receives an investigator safety report describing a SAE or other specific 
safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it 
along with the IB a nd will notify the IRB/IEC, if appropriate according to local requirements.  
Serious Adverse Event Reporting  
• Information about all SAEs is collected and recorded on the Adverse Event Form in the eCRF.  
• The investigator must also complete the Incyte Serious Adverse Event Report Form, in English.  
Refer to the Incyte Reference Guide for Completing the Serious Adverse Event Report Form.  
• Facsimile or email transmission of the Serious Adverse Event Report Form is the preferred method 
to transmit this information to the PhV/designee.  The contact [CONTACT_89208]'s 
study -specific representatives is listed in the Study Manual provided to each site.  The original copy 
of the Serious Adverse Event Report Form and the confirmation sheet must be kept at the st udy site.  
• Follow -up information is recorded on an amended or new Serious Adverse Event Report Form, with 
an indication that it is follow -up to the previously reported SAE and the date of the original report.  
The follow -up report should include information  that was not provided on the previous Serious 
Adverse Event Report Form, such as the outcome of the event (eg, resolved or ongoing), treatment 
provided, action taken with study drug because of the SAE (eg, dose reduced, interrupted, or 
discontinued), or p articipant disposition (eg,  continued or withdrew from study participation).  Each 
recurrence, complication, or progression of the original event should be reported as follow -up to that 
event, regardless of when it occurs.  
• In rare circumstances and in the absence of facsimile or computer equipment, notification by 
[CONTACT_9337] a copy of the Incyte Serious Adverse Event Report Form sent by 
[CONTACT_22855].  Initial notification via telephone does not replace the need for the  
investigator to complete and sign the Serious Adverse Event Report Form within the designated 
reporting time frames.  
• Contacts for SAE reporting can be found in the Study Manual.  
9.5. Emergency Unblinding of Treatment Assignment  
In a medical emergency, if the investigator deems it necessary to determine optimal medical 
management of the participant, emergency unblinding will be performed exclusively by [CONTACT_1268] [INVESTIGATOR_754338].  The IRT 
system has an op tion to select for "Emergency Code Break" action for a given participant.  After 
entering the 6 -digit study drug tube number and verification of the unmasking information, the 
investigator/subinvestigator will proceed to either final confirmation or cancel lation of the code 
break procedure.  
If a participant's treatment assignment is unblinded, the sponsor or its designee must be notified 
immediately by [CONTACT_352953] -up with an email.  
If an investigator, site personnel performing assessments, or partici pant is unblinded, the 
participant must be withdrawn from the study treatment, unless there are ethical reasons to have 
the participant remain on the study treatment.  In these cases, the investigator must obtain 
specific approval from the sponsor's (or it s designee's) medical monitor for the participant to 
continue in the study.  
Incyte Corporation  Page [ADDRESS_1032436] interfered with the effectiveness of a contraceptive medication o r method.  When a 
pregnancy has been confirmed in a participant during maternal or paternal exposure to study 
drug, the following procedures should be followed in order to ensure safety:  
• The study drug must be discontinued immediately.  
• The investigator mus t complete and submit the Incyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy.  
Data on fetal outcome are collected for regulatory reporting and drug safety evaluation.  
Follow -up should be conduc ted for each pregnancy to determine outcome, including spontaneous 
or voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by [CONTACT_89210]-baby [CONTACT_765].  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by [CONTACT_89211].  Pregnancy follow -up information should be 
recorded on the same form and should include an assessment o f the possible causal relationship 
to the sponsor's study drug to any pregnancy outcome, as well as follow -up to the first well -baby 
[CONTACT_89212], whichever is later.  Refer to the Incyte 
Reference Guide for Completi ng the Clinical Trial Pregnancy Form.  
Any SAE occurring during pregnancy of a study participant must be recorded on the 
Serious Adverse Event Report Form and submitted to the sponsor or designee.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal  death, stillbirth, congenital 
anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and 
must be reported as described in Section  9.4.  If an abnormal pregnancy outcome is reported in a 
study participant's partner, the event should be reported to the sponsor on the Clinical Trial 
Pregnancy Form.  
9.7. Warnings and Precautions  
Special warnings or precautions for the study drug, derived from safety information collected by 
[CONTACT_3552], are presented in the  ruxolitinib cream  IB.  Additional safety 
information collected between IB updates will be communicated in the  form of Investigator 
Notifications.  Any important new safety information should be discussed with the participant 
during the study, as necessary.  If new significant risks are identified, they will be added to the 
ICF. 
9.8. Product Complaints  
The sponsor coll ects product complaints on study drugs and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and facilitate 
process and product improvements.  
All product complaints associated with material  packaged, labeled, and released by [CONTACT_319862].  All product complaints associated with other 
study material will be reported directly to the respective manufacturer.  
Incyte Corporation  Page 53 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  The investigator or his/her designee is responsible for reporting a complete description of the 
product complaint via email or other written communication to the sponsor contact [CONTACT_147111].  Any AE associated with a product 
complaint should b e recorded as described in Section  9.3. 
If the investigator is asked to return the product for investigation, he/she will return a copy of the 
product complaint communication with the product.  
9.9. Treatment of Overdose  
There has been no clinical experience with overdose of ruxolitinib cream.  Treatment of 
overdose should consist of general supportive measures.  
10. STATISTICS  
10.1. Sample Size Determination  
Any eligible participants will be enrolled from the 2 parent Phase 3 studies, INCB  [ZIP_CODE] -306 
and INCB  [ZIP_CODE] -307.  The sample size is not based on any statistical power calculations.  
10.2. Populations for Analysis  
Table  10 presents the populations for analysis.  
Table  10: Populations for Analysis  
Population  Description  
Full analysis set  
(FAS)  All participants enrolled in the study who receive at least 1 dose of study drug 
(ruxolitinib cream or vehicle) at or after Week 52.a 
Intent -to-treat in 
long-term 
extension  
(ITT -Ext) All participants who achieve ≥ F -VASI90 at Week 52a and are randomized.  
Treatment groups for this population will be defined according to the treatment 
assignment at the time of randomization regardless of the actual study medication 
the particip ant might take the study.  
PK evaluable  The PK evaluable population includes participants who received at least [ADDRESS_1032437] 1 measurable postdose PK 
sample/assessment.  The study pharmacokineticist will review data lis tings of 
participant administration and sample records to identify participants to be 
excluded from the analysis.  
PK/PD evaluable  The PK/PD evaluable population includes participants who received at least 
1 dose of study drug (ruxolitinib cream or vehicle ) and provided at least 
1 measurable/evaluable postdose PK/PD sample/assessment.  The study 
pharmacokineticist will review data listings of participant administration and 
sample records to identify participants to be excluded from the analysis.  
a Week [ADDRESS_1032438] visit of the treatment extension study (visits are named to reflect continuation from the parent 
study).  
Incyte Corporation  Page 54 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  10.3. Level of Significance  
The primary and key secondary endpoints will be tested in a fixed sequence at 2 -sided α = 0.05 
level, that is, the key secondary endpoint will be tested only if the primary is rejected.  No formal 
statistical tests will be performed for other endpoints.  All confidence intervals will be 95%.  
10.4. Statistical Analys es 
10.4.1.  Efficacy Analysis  
Efficacy endpoints are listed in Section  3. 
For all complete or near -complete responders in the ITT -Ext population  (defined as achieving 
F-VASI90 at Week  52) in the treatment extension period, the events can be defined as follows:  
• Relapse is defined as a loss of F -VASI75 response assessed as percentage change 
from the baseline (Day 1 of the parent study) on F -VASI < 75%.  
• Loss of complete or near -complete response is defined as participants who do not 
maintain an F -VASI90.  
For relapse, a binary variable event is defined to be equal to 1 (Yes) when the value is greater or 
equal to 75% and 0 (No) for less than 50%.  
For l oss of F -VASI90 response, a categorical variable event is defined to be equal to 1 (Yes) 
when the value is greater or equal to 90% and 0 (No) for less than 90%.  
The time to relapse or loss of adequate response is defined as the number of days from the 
Week  [ADDRESS_1032439] evaluation date at which the participant has met the criteria.  
For participants who discontinue early or who complete without meeting criteria for the event, 
the time -to-event will be censored and defined as the number of da ys from the Week  52 
randomization to the participant’s last evaluation date.  
The time to event data will be assessed using the Kaplan -Meier product limit method.  Treatment 
comparisons between ruxolitinib cream 1.5% BID to vehicle will be performed using t he 
log-rank test.  Hazard ratios and the corresponding 95% confidence intervals will be estimated 
using the Cox proportional hazards model.  
The incidence of relapse or loss of adequate response following the Week  52 randomization will 
be summarized by [CONTACT_754359] 1.5% BID and vehicle at each timepoint.  
Other efficacy endpoints will be summarized in FAS.  Descriptive summaries for continuous 
variables will include, but not be limited to, the number of observations, mean, standard 
deviation, median, min imum, and maximum.  Descriptive summaries for categorical variables 
will include the number and percentage of participants in each category.  
For all relapse participants, the time to regaining F -VASI75/90 response is defined as the number 
of days from the start of the retreatment of ruxolitinib cream 1.5% BID to the first visit at which 
the participant has regained the F -VASI75/90 response.  For participants who discontinue or 
complete treatment before regaining F -VASI75/90, the time to regaining F -VASI75/[ADDRESS_1032440] limit method.  
Incyte Corporation  Page 56 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  11. SUPPORTING DOCUMENTA TION AND OPERATIONAL 
CONSIDERATIONS  
11.1. Investigator Responsibilities  
• The Protocol, Protocol amendments, ICF, IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC before the s tudy is initiated.  
• The investigator is responsible for ensuring that the safety reports provided by [CONTACT_89222], the 
policies and procedures established by [CONTACT_1201]/IEC, and institutional  requirements.  
• Any amendments to the Protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
• The investigator will be responsible  for the following:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC.  
− Notifying the IRB/IEC of SAEs or other significa nt safety findings as required by 
[CONTACT_1744]/IEC procedures.  
− Providing oversight of the conduct of the study at the site and adherence to GCP, 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country -specific regulations.  
• Adhering to the Protocol as described in this document and agreeing that changes to 
the Protocol procedures, with the exception of medical emergencies, must be 
discussed and approved, first, by [CONTACT_89223], second, by [CONTACT_5040]/IEC.  Each investigator is  responsible for enrolling participants who have met 
the specified eligibility criteria.  
• Retaining records in accordance with all local, national, and regulatory laws but for a 
minimum period of at least [ADDRESS_1032441] article for 
investigation to ensure the availability of study documentation should it b ecome 
necessary for the sponsor or a regulatory authority to review.  
− The investigator must not destroy any records associated with the study without 
receiving approval from the sponsor.  The investigator must notify the sponsor or 
its designee in the event  of accidental loss or destruction of any study records.  If 
the investigator leaves the institution where the study was conducted, the sponsor 
or its designee must be contact[CONTACT_89224].  
Incyte Corporation  Page 57 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  − All eCRF data entered by [CONTACT_4179] (including audit trail), as well as computer 
hardware and software (for accessing the data), will be maintained or made 
available at the site in compliance with applicable record retention regulations.  
The sponsor will retain the original eCRF data and  audit trail.  
11.2. Data Management  
Data management will be performed in a validated EDC system.  The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant.  
The site will be provided with eCRF completion  guidelines for instructions on data entry in the 
eCRF.  The study monitor will reference the Monitoring Plan in order to ensure that each issue 
identified is appropriately documented, reported, and resolved in a timely manner in accordance 
with the plan's  requirements.  Other data outside the EDC system required in the study conduct 
of the Protocol such as documents or results transmitted to the sponsor via a central laboratory or 
specialized technical vendors, and as designated by [CONTACT_456], will have t heir own data flow 
management plans, or study charters, or biomarker plans, as applicable.  
The sponsor (or designee) will be responsible for:  
• Managing the integrity of the data and the quality of the conduct of the study, such as 
ensuring that study monito rs perform ongoing source data verification to confirm that 
data entered into the eCRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the s tudy is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements.  
• Managing and reconciling the data generated, and/or collected including documents 
and results su ch as laboratory or imaging data analyzed centrally by a designated 
vendor of the sponsor.  
The investigator will be responsible for:  
• Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF.  
• Delivering, or ensuring the d elivery of, all other results, documents, data, know -how, 
or formulas relating to the study to the sponsor or designee electronically and/or 
centrally (eg, laboratory data, imaging data, biomarker data, photographs, diary data), 
or as otherwise specified i n the Protocol.  
• Verifying that data entries are accurate and correct by [CONTACT_108125].  
• Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF, or sent to a central vendor designate d by [CONTACT_456], or as 
described in other study and data flow manuals.  
− Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected.  Source documents are filed at the 
investigator's site.  
Incyte Corporation  Page 58 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  − Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator may need to request previous medical records or transfer records, 
depending on the st udy.  Also, current applicable medical records must be 
available.  
• May have responsibility for sending participants’ data, either as unique samples, or 
copi[INVESTIGATOR_014], or photographs, to be evaluated centrally or analyzed centrally, or both, by a 
qualified vendor d esignated by [CONTACT_456].  
• Permitting study -related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by [CONTACT_89225].  
− Monitoring:  Qualified representatives of the s ponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan.  The 
investigator must allow the study monitors to review any study materials and 
participant records at each monitoring visit.  
− Auditing:  Qualified represent atives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate compliance with the Protocol, 
applicable local clinical study regulations, and overall study conduct.  The 
investigator must allow the auditors to review ori ginal source records and study 
documentation for all participants.  
− Regulatory inspection:  Regulatory authorities may conduct an inspection of the 
study and the site at any time during the development of an investigational 
product.  The investigator and st aff are expected to cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other study 
related documents.  The investigator must immediately notify the sponsor when 
contact[CONTACT_754360].  
11.3. Data Privacy and Confidentiality of Study Records  
The investigator and the sponsor or its designee must adhere to applicable data privacy laws and 
regulations.  The investigator and the sponsor or its designee are responsi ble for ensuring that 
sensitive information is handled in accordance with local requirements (eg, HIPAA).  
Appropriate consent and authorizations for use and disclosure and/or transfer (if applicable) of 
protected information must be obtained.  
Participant names will not be supplied to the sponsor or its designee.  Only the participant 
number and the participant's initials (participant's initials will only be recorded if allowable by 
[CONTACT_427]) will be recorded in the eCRF, where permitted; if the pa rticipant's name 
[CONTACT_75502] (eg, laboratory report), it must be obliterated on the copy of the 
document to be supplied to the sponsor or its designee.  Study findings stored on a computer will 
be stored in accordance with local data prot ection laws.  
Incyte Corporation  Page [ADDRESS_1032442] to 
21 CFR Part 54 – Financial Disclosure by [CONTACT_6230] (ie, "covered studies") are 
required to submit a completed Cl inical Investigator Financial Disclosure Form that sufficiently 
details any financial interests and arrangements that apply.  For the purpose of this regulation, 
"clinical investigator" is defined as any investigator or subinvestigator who is directly invo lved 
in the treatment or evaluation of research participants, including the spouse and each dependent 
child of the clinical investigator or subinvestigator.  These requirements apply to both US and 
foreign clinical investigators conducting covered clinical  studies.  
Any new clinical investigators added to the covered clinical study during its conduct must also 
submit a completed Investigator Financial Disclosure Form.  During a covered clinical study, 
any changes to the financial information previously repor ted by a clinical investigator must be 
reported to the sponsor or its designee.  At the conclusion of the covered clinical study, the 
clinical investigators will be reminded of their obligations.  In the event that the clinical 
investigator is not reminded , they nevertheless will remain obligated to report to the sponsor or 
its designee any changes to the financial information previously reported, as well as any changes 
in their financial information for a period of 1 year after completion of the covered cl inical study.  
11.5. Publication Policy  
By [CONTACT_89228], the investigator and his or her institution agree that the results of 
the study may be used by [CONTACT_456], Incyte Corporation (Incyte), for the purposes of national 
and international registra tion, publication, and information for medical and pharmaceutical 
professionals.  Study results will be published in accordance with applicable local and national 
regulations.  The sponsor commits to also adhere to supranational/international rules regardi ng 
publishing research results, as set by [CONTACT_352983].  If necessary, the authorities will 
be notified of the investigator's name, address, qualifications, and extent of involvement.  The 
terms regarding the publication of study results are co ntained in the agreement signed with the 
sponsor or its designee.  A signed agreement will be retained by [CONTACT_3552].  
The results of this study may be published or presented at scientific meetings.  If this is foreseen, 
the investigator ag rees to submit all manuscripts or abstracts to the sponsor before submission.  
This allows the sponsor to protect proprietary information and to provide comments.  
The sponsor will comply with the requirements for publication of study results.  In accordanc e 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data.  In this case, a 
coordinating investigator [INVESTIGATOR_12992].  
Authorship will be determined in line with International Committee of Medical Journal Editors 
authorship requirements.  
11.6. Study and Site Closure  
The sponsor or designee reserves the right to close the study site or terminate the study at any 
time for any rea son at the sole discretion of the sponsor.  Study sites will be closed upon study 
completion.  A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
Incyte Corporation  Page 60 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  The inves tigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]:  
• Failure of the investigator to comply with the Protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines.  
• Inadequate recruitment of participants by [CONTACT_093].  
• Discontinuation o f further study treatment development.  
Incyte Corporation  Page 63 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  APPENDIX  A. ELIGIBILITY CRITERIA  FROM STUDIES 
INCB  [ZIP_CODE] -306 AND I NCB  [ZIP_CODE] -307 
INCB [ZIP_CODE] -306 and -307 Inclusion Criteria:  
Participants were eligible to be included in study INCB [ZIP_CODE] -306 or study INCB [ZIP_CODE] -307 
only if all of the following criteria applied:  
1. Adolescents and adults aged ≥ 12 years.  
2. Participants with a clinical diagnosis of non -segmental vitiligo with depi[INVESTIGATOR_352850] ≥ 0.5% BSA on the face, ≥ 0.5 F -VASI, ≥ 3% BSA on nonfacial areas, 
≥ 3 T-VASI,  and total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.  
3. Parti cipants who agree to discontinue all agents used to treat vitiligo from screening 
through the final safety follow -up visit.  Over -the-counter preparations deemed 
acceptable by [CONTACT_352932].  
4. Male and female participa nts must be willing to take appropriate contraceptive measures 
to avoid pregnancy or fathering a child for the duration of study participation with the 
exception of the following:  
a. Females of non -childbearing potential (ie, or surgically sterile with a hyst erectomy 
and/or bilateral oophorectomy OR postmenopausal, ≥ 12 months of amenorrhea 
without an alternative medical cause).  
b. Prepubescent adolescents.  
Note:  Information about specific types of acceptable contraceptive measures and 
duration of contraceptive use are provided in Appendix  B. 
5. For adult participant, ability to comprehend and willingness to sign an ICF; for 
adolescent participant, written i nformed consent of the parent(s) or legal guardian and 
written assent from the adolescent participant.  
Note:  Adolescents, who during the course of the study become legal adults, will be asked 
for their consent to continue the study, and in the event of la ck thereof, will be 
discontinued from further participation.  
INCB [ZIP_CODE] -306 and -307 Exclusion Criteria:  
Participants were excluded from study INCB [ZIP_CODE] -306 and study INCB [ZIP_CODE] -307 if any of 
the following criteria applied:  
1. Participants who have no pi[INVESTIGATOR_754339].  
2. Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other 
skin depi[INVESTIGATOR_262807] (eg, pi[INVESTIGATOR_312303], pi[INVESTIGATOR_80166], leprosy, postinflammatory 
hypopi[INVESTIGATOR_371], progressive macule hypomelanosis, nevus anemicus, chemical 
leukoderma, and tinea versicolor).  
3. Participants who have used depi[INVESTIGATOR_352901] (eg, monobenzone) for past 
treatment of vitiligo or other pi[INVESTIGATOR_312294].  
Note:  Prior use of hydroquinone i s not prohibited (as it is a bleaching agent, not a 
depi[INVESTIGATOR_352852]).  
Incyte Corporation  Page 64 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  4. Participants with concurrent conditions and history of other diseases:  
a. Any other skin disease that, in the opi[INVESTIGATOR_871], would interfere with 
the study medication  application or study assessments.  
b. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes 
zoster, chicken pox) within 1 week before baseline.  
c. Conditions at baseline that would interfere with evaluation of vitiligo.  
d. Any serious illness or medical, physical, or psychiatric condition(s) that, in the 
investigator's opi[INVESTIGATOR_1649], would interfere with full participation in the study, including 
administration of study drug and attending required study visits; pose a significant 
risk to the participant; or interfere with interpretation of study data.  
Examples include but are not limited to the following:  
− Clinically significant or uncontrolled cardiac disease, including unstable angina, 
acute myocardial infarction within 6 months from Day 1 o f study drug 
administration, [LOCATION_001] Heart Association Class III or IV congestive heart 
failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood 
pressure > 150/90 mmHg) unless approved by [CONTACT_7195]/sponsor.  
− History of throm bosis, including deep venous thrombosis and pulmonary 
embolism.  
− Participants with concurrent malignant disease or a history of that in the 5 years 
preceding the baseline visit except for adequately treated nonmetastatic 
malignancies.  
− Current and/or history of liver disease, including known hepatitis B or C, with 
hepatic or biliary abnormalities.  
− Current and/or history of tuberculosis.  
− History of alcoholism or drug addiction within 1 year before screening or current 
alcohol or drug us e that, in the opi[INVESTIGATOR_871], will interfere with the 
participant's ability to comply with the administration schedule and study 
assessments.  
− Participants who are committed to an institution by [CONTACT_754361].  
5. Participants using any of the following treatments within the indicated washout period 
before baseline:  
a. 1 week:   Topi[INVESTIGATOR_352853], for example, corticosteroids, 
calcineurin, and phosphodieste rase type 4 inhibitors or retinoids.  
b. 4 weeks:  
− Melanocyte -stimulating agents (eg, afamelanotide).  
− Immunomodulating systemic medications (eg, corticosteroids, methotrexate, 
cyclosporine).  
− Any other systemic therapi[INVESTIGATOR_427426]/visible 
light or impact skin pi[INVESTIGATOR_371], for example, tetracyclines, metoxypsoralens.  
Incyte Corporation  Page 65 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  − Received live vaccine.  
Note:  Live vaccine is prohibited during the course of the study and within 
4 weeks after the EOT visit.  
c. 8 weeks:   Laser or any kind of pho totherapy, including tanning bed or intentional UV 
exposure.  
d. 5 half -lives  or 12 weeks , whichever is longer:  Biologic agents, investigational or 
experimental therapy or procedures for vitiligo.  Investigational biologics should be 
discussed with the sponso r to determine whether a longer period of discontinuation is 
required.  
6. Participants who have previously received JAK inhibitors, systemic or topi[INVESTIGATOR_2855].  
7. Participants with clinically significant abnormal laboratory values at screening:  
a. Hemoglobin (< 10 g/dL).   
b. Liver function tests:  
− AST or ALT ≥ 2 × ULN.  
− Alkaline phosphatase and/or bilirubin > 1.5 × ULN (isolated bilirubin 
> 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%).  
c. Severe renal disease (with creatinine clearance <  30 ml/min) or renal disease 
requiring dialysis.  
d. Clinically significant abnormal TSH or free T4 at screening as determined by [CONTACT_1275].  
e. Positive serology test results at screening for HIV antibody.  
8. Body mass index < 17 or > 40 kg/m2 for adult participant s (age ≥ 18 years).  BMI -for-age 
in the < 5th percentile or ≥ 85th percentile range for adolescent participants (age ≥ 12 to 
< 18 years) according to the CDC BMI Percentile Calculator for Child and Teen ( 2019 ). 
Note:  Adolescent  BMI criterion added based on INCB [ZIP_CODE] -306 and INCB [ZIP_CODE] -307 
Protocol Amendment 3 -US-CA (dated 13 MAR 2020).  
9. Pregnant or lactating participants, or those considering pregnancy during the period of 
their study participation.  
10. Participants who, in the opi[INVESTIGATOR_871], are unable or unlikely to comply with 
the administration schedule and study evaluations.  
11. Employees of the sponsor or investigator or are otherwise dependents of them.  
12. Participants with known allergy or  reaction to any component of the study formulation.  
13. Participants who live with anyone participating in any current Incyte -sponsored 
ruxolitinib cream study.  
Incyte Corporation  Page 66 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  APPENDIX  B. INFORMATION REGARDIN G EFFECTIVENESS OF 
CONTRACEPTIVE METHOD S 
For male participants in the study:  
Male participants should use a condom during treatment through [ADDRESS_1032443] had a vasectomy qualify as having met the requirement 
for a highly e ffective birth control method.  
For female participants in the study:  
The following methods that can achieve a failure rate of less than 1% per year when used consistently 
and correctly are considered as highly effective birth control methods:  
• Combined (estrogen and progestogen containing) hormonal contraception associated with 
inhibition of ovulation  
− oral 
− intravaginal  
− transdermal  
• Progestogen -only hormonal contraception associated with inhibition of ovulation  
− oral 
− injectable  
− implantablea 
• Intrauterine devicea 
• Intrauterine hormone -releasing systema 
• Bilateral tubal occlusiona 
• Vasectomized partnera,b 
• Sexual abstinencec 
Acceptable birth control methods that result in a failure rate of more than 1% per year include:d 
• Progestogen -only oral hormonal contraception, where inhibition of ovulation is not the primary 
mode of action  
• Male or female cond om with or without spermicidee 
• Cap, diaphragm, or sponge with spermicidee 
• Tubal ligation  
a Contraception methods that in the context of this guidance are considered to have low user dependency.  
b Vasectomized partner is a highly effective method of avoiding pregnancy provided that part ner is the sole sexual 
partner of the woman of childbearing potential study participant and that the vasectomized partner has received 
medical assessment of the surgical success.  
c In the context  of this guidance, sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study treatments.  The 
reliability of sexual abstinence needs to b e evaluated in relation to the duration of the clinical study and the 
preferred and usual lifestyle of the participant.  
d Choices are for US and Canada participants only and include above less th an 1% failure rate methods.  
e A combination of male condom with either cap, diaphragm, or sponge with spermicide (double barrier methods) 
are also considered acceptable, but not highly effective,  birth control methods.  
Source:  Clinical Trial Facilitation and Coordination Group [ADDRESS_1032444] with the Class I ultra -high–potency 
preparations, which should only be used for limited time periods (2 -3 weeks).  Representative 
preparations by [CONTACT_352984].  These groups may vary depending on the 
formulation and conc entration and should be considered approximate.  In general, ointments are 
more potent than creams or lotions.  Potency is also increased when topi[INVESTIGATOR_427445].  
Potency  Class  Topi[INVESTIGATOR_754340]  I Clobetasol propi[INVESTIGATOR_225332], 0.05%  
Diflorasone diacetate  Ointment, 0.05%  
High  II Amcinonide  Ointment, 0.1%  
Betamethasone dipropi[INVESTIGATOR_352920], 0.05%  
Desoximetasone  Cream or ointment, 0.025%  
Fluocinonide  Cream, ointment or gel, 0.05%  
Halcinonide  Cream, 0.1%  
III Betamethasone dipropi[INVESTIGATOR_225332], 0.05%  
Betamethasone valerate  Ointment, 0.1%  
Diflorasone diacetate  Cream, 0.05%  
Triamcinolone acetonide  Ointment, 0.1%  
Moderate  IV Desoximetasone  Cream, 0.05%  
Fluocinolone acetonide  Ointment, 0.025%  
Fludroxycortide  Ointment, 0.05%  
Hydrocortisone valerate  Ointment, 0.2%  
Triamcinolone acetonide  Cream, 0.1%  
V Betamethasone dipropi[INVESTIGATOR_225334], 0.02%  
Betamethasone valerate  Cream, 0.1%  
Fluocinolone acetonide  Cream, 0.025%  
Fludroxycortide  Cream, 0.05%  
Hydrocortisone butyrate  Cream, 0.1%  
Hydrocortisone valerate  Cream, 0.2%  
Triamcinolone acetonide  Lotion, 0.1%  
Low VI Betamethasone valerate  Lotion, 0.05%  
Desonide  Cream, 0.05%  
Fluocinolone acetonide  Solution, 0.01%  
VII Dexamethasone sodium phosphate  Cream, 0.1%  
Hydrocortisone acetate  Cream, 1%  
Methylprednisolone acetate  Cream, 0.25%  
Source:  WHO [ADDRESS_1032445] of 
clinical trials.  In line with the European Medicines Agency Guidelines on the Management of 
Clinical Trials During the COVID -19 (Coronavirus) Pandemic ( 2020 ), the sponsor has issued the 
following Protocol considerations to ensure participant safety is maintained and adequate 
benefit/risk analyses are applied relative to the completion of study procedures and maint aining 
the investigational product supply chain.  
Recognizing the flexibility required to manage the impact of the pandemic on this clinical trial, 
additional details will be added to respective study manuals  and project plan documents and 
communicated to t he investigative sites as needed.  
Study Site Visits  
If local travel restrictions, isolation requirements, or the investigator's benefit/risk assessment 
determines it to be unsafe for participants to attend study visits at the investigational site, the site  
staff may elect to pursue the following:  
• In order to minimize participant  risk, study visits (except Week 52 and Week 104 
visits) may be conducted via telemedicine modalities (phone or video).  At a 
minimum, a review of AEs, concomitant medications, and s tudy drug compliance 
must be completed.  Periodic on -site visits should be conducted whenever feasible.  
The physician efficacy assessments must not be conducted by [CONTACT_630].  
• Week [ADDRESS_1032446] Dispensation and Distribution  
In order to ensure the continuity of providing their participants' clinical supplies within the 
constraints imparted by [CONTACT_47098], the site staff can decide to supply study drug to 
participants.  Adequate supplies of study drug as determined by [CONTACT_754362] 
12 weeks can be shipped to the participants by [CONTACT_754363] 
(eg, the study pharmacy staff) using a third -party service if duly authorized by [CONTACT_2299].  
The study si te may use their own preferred courier, provided the courier adheres to certain 
standards (eg, use of personal protection equipment, maintenance of temperature -controlled 
transit environment) or one centrally contracted by [CONTACT_456].  
Clinical Trial Monit oring  
Study monitoring visits may be postponed; however, the site monitor will continue to employ 
off-site monitoring practices such as routine communication methods (eg, phone calls, emails, 
video visits) with the sites to get information on trial progress, participant status, and information 
on issue resolution.  The study monitor may remotely review data entered into the EDC for 
accuracy and completeness.  Remote source data verification may be implemented with 
agreement of the principal investiga tor and institution, as applicable.  
Incyte Corporation  Page [ADDRESS_1032447] from the hospi[INVESTIGATOR_754341] b y the study coordinator/data manager with suitable 
training.  The study drug can be returned to the sponsor by [CONTACT_5035][INVESTIGATOR_490532], or it 
can be destroyed in accordance with local practices, if applicable, and with sponsor approval.  
 
Incyte Corporation  Page 70 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  APPENDIX  E. PROTOCOL AM ENDMENT SUMMARY OF C HANGES  
Document  Date  
Amendment 1 : 28 SEP 2020  
Amendment 2 :  10 NOV 2020  
Amendment 2 ( 10 NOV 2020)  
Overall Rationale for the Amendment:  
The main purpose of this amendment is to add language to the Protocol to inform sites of 
alternative strategies to guarantee continuity of the clinical trial conduct and oversight in 
response to the COVID -19 pandemic.  
1. Appendix D, COVID -19 Pandemic Mitigation Strategies and Instructions  
Description of change:  Added Appendix D to the Protocol  and added 
cross-references to the appendix to relevant sections.  
Rationale for change:   To provide sites with Protocol -related guidance in response 
to the COVID -[ADDRESS_1032448] been incorporated throughout the Protocol and are noted in the 
redline version of the amendment.  
Incyte Corporation  Page 71 of 71 
Protocol INCB [ZIP_CODE] -308 Am 2  Version 3     10 NOV 2020  
CONFIDENTIAL  Amendment 1 (28 SEP 2020)  
Overall Rationale for the Amendment:   The primary purpos e of this amendment is to 
accommodate the EMA PDCO recommendation regarding the DLQI/CDLQI endpoint and to 
align the PK endpoints with those of parent studies INCB [ZIP_CODE] -306 and INCB [ZIP_CODE] 307.  
1. Title Page; Section 1, Protocol Summary  
Description of change:   Added TRuE -V LTE to the Protocol title.  
Rationale for change:   To include the short name [CONTACT_754364].  
2. Section 1, Protocol Summary (Table 1:  Primary and secondary Objectives and 
Endpoints); Section 3, Objectives and Endpoints (Table 8:  Objectives and 
Endpoints)  
Description of change:  Moved endpoint for DLQI/CDLQI from exploratory to 
secondary.  
Rationale for changes:  To address EMA PDCO recommendation.  
2. Section 1, Protocol Summary (Table 1:  Primary and Secondary Objectives and 
Endpoints); Section 3, O bjectives and Endpoints (Table 8:  Objectives and 
Endpoints)  
Description of change:   Moved endpoint for PK from exploratory to secondary.  
Rationale for change:   To align with INCB [ZIP_CODE] -306 and INCB [ZIP_CODE] -307 parent 
studies.  
3. Section 1, Protocol Summary (Ta ble 3:  Schedule of Activities); Section 8.4, 
Pharmacokinetic Assessments  
Description of change:   Added clarifications that PK samples should be collected at 
predose and the time of the last study drug application is to be recorded in the eCRF.  
Rationale f or change:   To align PK sample collection procedures with INCB [ZIP_CODE] -306 
and INCB [ZIP_CODE] -307 parent studies.  
4. Section 5.1, Inclusion Criteria (Inclusion Criteria 5a and 6)  
Description of change:   Clarified wording of inclusion criteria.  
Rationale for change:   To align with INCB [ZIP_CODE] -306 and INCB [ZIP_CODE] -307 parent 
studies.  
5. Section 10.4.3, Other Analyses  
Description of change:  Corrected PK data analysis method.  
Rationale for change:   Ruxolitinib plasma concentration data analysis is not based on a 
population PK modeling approach.  
6. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline ve rsion of the 
amendment.  
Signature [CONTACT_11032]-CLIN-010468 v3.0
Signature [CONTACT_11032]-CLIN-010468 v3.0Approval
Approver
10-Nov-2020 14:33:43 GMT[PHONE_006]
Approval
Approver
10-Nov-2020 14:35:05 GMT[PHONE_006]
Approval
Approver
10-Nov-2020 15:18:06 GMT[PHONE_006]
Approval
Approver
11-Nov-2020 14:35:04 GMT[PHONE_006]
Approval
Approver
11-Nov-2020 20:52:23 GMT[PHONE_006]
